Nothing Special   »   [go: up one dir, main page]

USRE43878E1 - Amidophenoxyindazoles useful as inhibitors of c-Met - Google Patents

Amidophenoxyindazoles useful as inhibitors of c-Met Download PDF

Info

Publication number
USRE43878E1
USRE43878E1 US13/374,053 US201113374053A USRE43878E US RE43878 E1 USRE43878 E1 US RE43878E1 US 201113374053 A US201113374053 A US 201113374053A US RE43878 E USRE43878 E US RE43878E
Authority
US
United States
Prior art keywords
methyl
mmol
fluoro
indazol
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US13/374,053
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Zhipei Wu
Wei Jennifer YANG
Boyu Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US13/374,053 priority Critical patent/USRE43878E1/en
Application granted granted Critical
Publication of USRE43878E1 publication Critical patent/USRE43878E1/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • c-Met is a member of the tyrosine kinase growth factor receptor family. c-Met expression occurs in endothelial, epithelial, and mesenchymal cells. Binding to c-Met of the endogenous ligand, hepatocyte growth factor (HGF), promotes cell migration, proliferation, and invasion.
  • HGF hepatocyte growth factor
  • c-Met is implicated in the progression of certain tumors.
  • c-Met overexpression has been shown in numerous tumor types including colon, breast, renal, lung, hemangiomas, squamous cell myeloid leukemia, melanomas, glioblastomas, and astrocytomas.
  • Activation of tumor cell c-Met receptors enhances tumor cell proliferation, invasion/metastasis, and resistance to apoptosis and cytotoxic therapies.
  • the present invention provides novel amidophenoxyindazole compounds believed to have clinical use for treatment of cancer through inhibiting c-Met. Preferred compounds of the present invention are also believed to provide an improvement in potency over certain other c-Met inhibitor compounds found in the art.
  • the present invention provides compounds of Formula I:
  • R 1 is H or methyl
  • R 2 is amino, dimethylamino, fluoro, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazolyl optionally substituted with two methyl substituents, 2-methoxy-pyrimidin-5-yl, 4-methylsulfonylphenyl, tetrahydro-2H-pyran-4-ylamino, (tetrahydro-2H-pyran-4-yl)amino carbonyl, or a morpholin-4-yl substituent:
  • R a , R b and R c are independently selected from H or methyl
  • R 3 is H or F
  • R 4 is H, methyl, piperidin-1-ylmethyl, morpholin-4-ylmethyl, or pyrazol-1-ylmethyl;
  • R 5 is H or F
  • X is CH ⁇ N, CH ⁇ CH, CH ⁇ C(CH 3 ), C(CH 3 ) ⁇ CH, C(CH 3 ) ⁇ N, N(CH 3 ), or C(morpholin-4ylmethyl) ⁇ CH C(morpholin-4-ylmethyl) ⁇ CH;
  • the present invention provides a method of treating cancer selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • This invention also provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use as a medicament. Additionally, this invention provides use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer.
  • these cancers are selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer.
  • this invention provides a pharmaceutical composition for treating cancer selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the compounds of the present invention are capable of forming salts.
  • the compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); L. D. Bighley, S. M. Berge, D. C. Monkhouse, in “Encyclopedia of Pharmaceutical Technology’. Eds. J. Swarbrick and J. C.
  • Preferred pharmaceutically acceptable salts of the compounds of the present invention are the methanesulfonate salts.
  • R 1 is H
  • R 1 is methyl
  • R 2 is amino, dimethylamino, cyclopropyl, 6-methyl-pyridin-3-yl, pyrazol-4-yl, or a morpholin-4-yl of the formula:
  • R 2 is amino, dimethylamino, pyrazol-4-yl, or morpholin-4-yl
  • R 2 is pyrazo-4-yl
  • R 1 is methyl and R 2 is pyrazol-4-yl
  • R 1 is methyl, R 2 is pyrazol-4-yl, and R 3 is F;
  • R 4 is H, methyl, or morpholin-4-ylmethyl
  • R 1 is methyl, R 2 is pyrazol-4-yl, R 3 is F, and R 4 is H;
  • R 1 is methyl, R 2 is pyrazol-4-yl, R 3 is F, R 4 is H, and R 5 is H;
  • R 1 is methyl, R 2 is pyrazol-4-yl, R 3 is F, R 4 is H, and R 5 is F;
  • (p) X is CH ⁇ CH or CH ⁇ C(CH 3 );
  • R 1 is methyl
  • R 2 is pyrazol-4-yl
  • R 3 is F
  • R 4 is H
  • R 5 is H
  • X is CH ⁇ CH or CH ⁇ C(CH 3 );
  • R 1 is methyl, R 2 is pyrazol-4-yl, R 3 is F, R 4 is H, R 5 is F, and X is CH ⁇ CH or CH ⁇ C(CH 3 );
  • R 1 is methyl
  • R 2 is pyrazol-4-yl
  • R 3 is F
  • R 4 is H
  • R 5 is H or F
  • X is CH ⁇ C(CH 3 );
  • R 1 is methyl
  • R 2 is pyrazol-4-yl
  • R 3 is F
  • R 4 is H
  • R 5 is H
  • X is CH ⁇ C(CH 3 );
  • R 1 is methyl
  • R 2 is pyrazol-4-yl
  • R 3 is F
  • R 4 is H
  • R 5 is F
  • X is CH ⁇ C(CH 3 ).
  • the compounds of the present invention can be prepared according to the following synthetic schemes by methods well known and appreciated in the art. Suitable reaction conditions for the steps of these schemes are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Likewise, it will be appreciated by those skilled in the art that synthetic intermediates may be isolated and/or purified by various well known techniques as needed or desired, and that frequently, it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, the skilled artisan will appreciate that in some circumstances, the order in which moieties are introduced is not critical.
  • the compounds of the present invention can be made by standard peptide coupling conditions well known to the skilled artisan.
  • a suitably substituted indazole aniline of formula (a) is reacted with an acid compound of formula (b), in the presence of a peptide coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole hydrate (HOBt), an appropriate base such as N-methylmorpholine, N,N-diisopropylethylamine (DIPEA), or triethylamine (TEA), in a suitable solvent such as dichloromethane (DCM), N,N-dimethylformamide (DMF) or tetrahydrofuran (THF) to provide the desired amide of the present invention.
  • a peptide coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimi
  • R 1′ is a suitable nitrogen protecting group such as tetrahydropyran (THP), or if R 2′ is a functional group protected by a nitrogen-protecting group, a de-protection step is needed to obtain the desired compound of the present invention.
  • THP tetrahydropyran
  • the compound of formula (a) can be prepared as illustrated in Scheme II, where R 1′ , R 2′ , and R 3 are as previously defined.
  • the compound of formula (f) can react with a properly substituted compound of formula (g) at elevated temperature, in the presence of a suitable base such as sodium bicarbonate in a proper solvent such as DMF to provide the compound of formula (e).
  • a suitable base such as sodium bicarbonate in a proper solvent such as DMF
  • the compound of formula (e) can be methylated with a proper methylation reagent such as methyl iodide in a suitable solvent such as THF with a suitable base such as potassium tert-butoxide to provide the compound of formula (d), where R 1′ is a methyl.
  • the compound of formula (e) can also be protected with a suitable protecting reagent such as 2,3-dihydropyran (DHP) in a appropriate solvent such as THF, in the presence of an acid such as CH 3 SO 3 H to provide the compound of formula (d), where R 1′ is a protecting group such as 2-tetrahydropyranyl.
  • a suitable protecting reagent such as 2,3-dihydropyran (DHP) in a appropriate solvent such as THF, in the presence of an acid such as CH 3 SO 3 H
  • an acid such as CH 3 SO 3 H
  • R 1′ is a protecting group such as 2-tetrahydropyranyl.
  • the compound of formula (d) can react under various transition-metal facilitated coupling conditions to provide the desired compound of formula (c) with a properly substituted R 2′ as previously defined. More specifically, if it is a carbon-carbon coupling, the compound of formula (c) can be made under coupling conditions such as a Suzuki coupling with a suitable boronic acid, an appropriate catalyst such as 1,1′-bis(diphenylphosphino)ferrocene palladium (II) chloride (PdCl 2 (dppf)), and a proper base such as CsF in a suitable solvent such as 1,4-dioxane at elevated temperature.
  • coupling conditions such as a Suzuki coupling with a suitable boronic acid, an appropriate catalyst such as 1,1′-bis(diphenylphosphino)ferrocene palladium (II) chloride (PdCl 2 (dppf)
  • a proper base such as CsF in a suitable solvent such as 1,4-dioxan
  • the compound of formula (c) can be made under coupling conditions such as a Buchwald-Hartwig coupling with a proper nitrogen-containing reactant such as morpholine, a suitable ligand such as 2-di-tert-butylphosphino-2′-methylbiphenyl, a base such as KOH, and a catalyst such as tris(dibenzylideneacetone)-dipalladium (0) (Pd 2 (dba) 3 ), in an appropriate solvent such as tert-butanol at elevated temperature.
  • the coupling reaction can be carried out under conventional heating conditions or under microwave reaction conditions well known to the skilled artisan.
  • the compound of formula (c) can be reduced to an amino compound under various reduction conditions well known to the skilled artisan. More specifically, the compound of formula (c) can react with stannous chloride in a suitable solvent such as ethyl acetate (EtOAc)/ethanol (EtOH) at an elevated temperature to give the desired compound of formula (a). If R 1′ is a nitrogen-protecting group such as 2-tetrohydropyranyl, the protecting group will be cleaved. R 1′ will be a proton after the reduction.
  • a suitable solvent such as ethyl acetate (EtOAc)/ethanol (EtOH)
  • the compound of formula (c) can also be reduced by reacting with N,N-dimethylhydrazine and FeCl 3 in a proper solvent such as methanol (MeOH), or H 2 /palladium on carbon (Pd/C) in proper solvent such as EtOH. Both reduction conditions will only reduce the nitro group to an amino group, and will leave the nitrogen-protecting group, R 1′ , untouched.
  • a proper solvent such as methanol (MeOH), or H 2 /palladium on carbon (Pd/C) in proper solvent such as EtOH.
  • 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole may also be prepared in the following 3 step process:
  • 2,4-Dibromo-5-(2-fluoro-4-nitrophenoxy)benzaldehyde (13.0 g, 31.0 mmol) is refluxed with methylhydrazine (4.3 g, 93 mmol) in THF (130 mL) for 2 hours.
  • the reaction is quenched with water (150 mL) and extracted with MTBE (2 ⁇ 150 mL).
  • the organic layer is washed with saturated sodium chloride aqueous solution (2 ⁇ 150 mL), dried with anhydrous sodium sulfate, and concentrated to obtain a solid.
  • the reaction mixture is heated at 150° C. for 25 min in a microwave reactor.
  • the reaction mixture is then concentrated and the residue is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 90% (A): 10%(B) to 60%(A):40%(B) over 60 min then to 50%(A):50%(B) for 20 min to give an orange solid as the desired product (410 mg, 39% yield).
  • 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (1.5 g, 3.4 mmol) is added to a 50 mL Genevac Carousel® tube and is suspended into the amylene hydrate (10 mL, 91.4 mmol) and N 2 is bubbled in suspension.
  • To the mixture is added 2-(di-tert-butylphosphino)-2′-methylbiphenyl (97.7 mg, 309 ⁇ mol), Pd 2 (dba) 3 (94.5 mg, 103 ⁇ mol) and DI water (0.3 mL), and N 2 bubbling is continued for 10 min.
  • the solid is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 95%(A):5%(B) to 75%(A):25%(B) over 70 min to give a light yellow solid as the desired product (410 mg, 25% yield). MS (m/z): 470.8 (M+H).
  • 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole 500 mg, 1.37 mmol
  • 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 73 mg, 123 ⁇ mol
  • Pd 2 (dba) 3 38 mg, 41 ⁇ mol
  • the mixture is suspended in toluene (5 mL, 47 mmol) and benzophenone imine (272 mg, 1.5 mmol) and sodium tert-butoxide (203 mg, 2.05 mmol) are added.
  • the mixture is heated at 150° C. for 20 min in a microwave reactor.
  • N-(diphenylmethylene)-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-amine (424 mg, 909 ⁇ mol) and EtOH (35 mL, 601 mmol).
  • ammonium formate 1000 mg, 15.9 mmol
  • 10% Pd/C 300 mg, 141 ⁇ mol
  • the solvent is removed and the residue is dissolved in DCM (150 mL) and distilled water (100 mL).
  • 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole 230 g, 653.2 mmol
  • DMF 3000 mL
  • K 2 CO 3 135.41 g, 979.78 mmol
  • the reaction mixture is cooled to 4.5° C. with an ice bath.
  • methyl iodide 92.71 g, 653.19 mmol
  • the reaction is allowed to stir for 20 min at the same temperature.
  • the reaction is allowed to warm to RT and stir for 13 hours.
  • the reaction mixture is monitored by liquid chromatography mass spectrometry.
  • This solid is then triturated with 1000 mL of DCM and 750 mL of MeOH overnight (about 14 hours). The solid is collected by filtration and rinsed with fresh DCM (100 mL) to give 55.5 g of desired material labeled (C). The mother liquor is concentrated and labeled (D). The organic layer from (A) and (B) are separated and concentrated. The residues from (A) and (B) are combined to give 185 g of crude as an orange solid labeled (E).
  • the crude compound (E) is dissolved in MeOH and DCM, and then the solution is divided into 3 portions. 600 g of silica gel is mixed with each portion of solution, and then the silica gel mixture is loaded into seven 270 g size empty cartridges. Seven 1.5 kg ISCO® columns are used with solvent system starting with 25% EtOAc in hexanes, then it is switched to 50% EtOAc in hexanes to give 62 g of the desired compound as a yellow powder labeled (F).
  • thermocouple To a 12 L round bottom flask equipped with overhead agitation, a thermocouple, heating mantle, condenser, and subsurface nitrogen sparge is added 1,4-dioxane (7.44 L) and water (1.67 L). The solution is purged with N 2 (inlet tube). Next 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole (595 g, 1.63 mol) is added and the solution is purged with N 2 again.
  • the material is about 60% desired product and about 40% 5-(2-fluoro-4-nitrophenoxy)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indazole.
  • the crude obtained is reprotected in the next step. It is assumed that 50% of the crude product is the 5-(2-fluoro-4-nitrophenoxy)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indazole.
  • tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (433.0 g, 952.8 mmol) followed by THF (6.5 L) and Pd/C (21.65 g, 10% Pd/C and 21.65 g, 5% Pd/C).
  • THF 6.5 L
  • Pd/C 21.65 g, 10% Pd/C and 21.65 g, 5% Pd/C
  • the mixture is allowed to stir at RT overnight.
  • the reaction mixture is diluted into EtOAc (300 mL) and washed with saturated aqueous sodium chloride (5 ⁇ 100 mL).
  • the combined aqueous solution is extracted with EtOAc (1 ⁇ 100 mL) and then the combined organic solutions are dried over N 2 SO 4 , filtered, and concentrated to dryness.
  • the solid is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in a DCM solution (B), gradient from 100% (A) to 80% (A):20% (B) over 70 min to give tert-butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate as a gold solid (2.20 g, 87% yield). MS (m/z): 653. (M+H), 675 (M+Na).
  • the solvent is removed and diluted into DCM (150 mL) and washed with saturated aqueous NaHCO 3 solution (2 ⁇ 100 mL).
  • the organic solution is dried with Na 2 SO 4 , and concentrated under reduced pressure to give a solid material.
  • the solid is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in DCM solution (B), gradient from 100% (A) to 75%(A):25%(B) over 70 min, held at this 75:25 ratio for 15 min to give the title compound as an off-white solid.
  • the solid is dissolved in hot EtOH (50 mL) followed by a portion-wise addition of distilled water (250 mL) causing a white solid to precipitate.
  • a 12 L round bottom flask is equipped with overhead agitation, a thermocouple, and a N 2 purge.
  • tert-Butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (404 g, 954.08 mmol) is dissolved in DMF (2 L) and charged to the flask.
  • DMF (1 L) is used to rinse the flask.
  • N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide hydrochloride (367 g, 0.62 mol) followed by DCM (7.34 L) and water (7.34 L).
  • Na 2 CO 3 (181.6 g, 1.71 mol) is added and the mixture is stirred at RT for 30 min. The pH is checked and found to be about 9.4. The mixture is filtered over polypropylene.
  • the solids are collected and placed into a 5 L round bottom flask. A 20% water/MeOH solution (2.6 L) is added and the slurry is stirred for 30 min. The slurry is filtered and the solids are washed with 20% water/MeOH (600 mL). The solids are placed in a vacuum oven at 35° C. overnight. The first weighing indicates 394 g (theoretical yield 324.8 g, about 121% mass recovery). TGA (Thermogravimetric analysis)/DSC (differential scanning calorimetry) shows about 17 wt % free water and 10-11 wt% volatile loss at the melt. The solids are dried at 55° C. in a vacuum oven with a N 2 sweep for 3.5 hours (354.7 g, about 109% mass recovery, NMR shows about 9.3 wt % DCM). No free water is present according to TGA/DSC. The material is sent for milling.
  • the jet mill (AljetTM 0101) in a glove bag is assembled inside a walk in hood and hooked up to N 2 to a 100 lb header.
  • the inlet pusher nozzle is adjusted for maximum draw and max nitrogen flow is introduced into the mill. Pressure readings are noted as 90 psi on pusher nozzle and 85 psi on both grind nozzles.
  • the starting material 353.4 g
  • the total milling time is 22 min and 25 second.
  • the calculated feed rate is 15.8 g/min (353.4 grams divided by 22.42 min).
  • the milled material (335.7 g, 95%) is obtained with 17.7 g loss.
  • Particle size analysis result of the milled material is d90 of 4.6 microns.
  • the solid is isolated by vacuum filtration and dried in a vacuum oven at 45° C. for 3 hours, resulting in 77% recovery.
  • the crystalline form shows a weight loss of 0.17% from 25-238° C. by TGA.
  • the form's onset of melting is 247.8° C.
  • N-(4-(6-(benzhydrylamino)-1-methyl-1H-indazol-5-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 100 mg, 149.7 ⁇ mol
  • DCM 15 mL, 15.6 mmol
  • triethylsilane 0.3 mL, 1.8 mmol
  • TFA 2 mL, 26.9 mmol
  • reaction mixture is stirred at RT overnight.
  • the reaction is diluted into EtOAc (50 mL) and washed with saturated aqueous sodium chloride (5 ⁇ 25 mL). Organic layers are dried over Na 2 SO 4 , filtered, and concentrated to dryness.
  • N-(3-fluoro-4-(6-(2-methylmorpholino)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 66 mg, 102.86 ⁇ mol
  • MeOH 5 mL, 123.54 mmol
  • MeSO 3 H 20.229 ⁇ L, 308.57 ⁇ mol
  • the reaction mixture is heated to 40° C. for 6 hours.
  • the reaction mixture is concentrated and dissolved in DCM (100 mL).
  • the following assays demonstrate that certain compounds of the present invention potently inhibit c-Met phosphorylation in cells, potently inhibit c-Met in vivo, and demonstrate dose dependent anti-tumor activity in certain xenograft models.
  • the kinase domain (KD) of human c-Met (from Gly 966 to Ser 1390, NCBI NM — 000245) is cloned into a pFastBac® RHT vector (Invitrogen, Carlsbad, Calif.).
  • the His-c-Met KD construct is transposed into Baculovirus DNA using a Bac-to-Bac® system (Invitrogen).
  • SF9 cells are infected with the recombinant baculovirus. The infected cells are harvested by centrifugation and the cell pellet is collected and stored at ⁇ 80° C.
  • Cells are lysed in buffer A (40 mM tris(hydroxymethyl)aminomethane (Tris), pH 7.5, 500 mM NaCl, 20% glycerol, and 10 mM imidazole). Cell lysates are homogenized and centrifuged. Supernatants are incubated with nickel-nitrilotriacetic (Ni—NTA) resin and loaded onto a column.
  • buffer A 40 mM tris(hydroxymethyl)aminomethane (Tris), pH 7.5, 500 mM NaCl, 20% glycerol, and 10 mM imidazole.
  • Cell lysates are homogenized and centrifuged. Supernatants are incubated with nickel-nitrilotriacetic (Ni—NTA) resin and loaded onto a column.
  • Ni—NTA nickel-nitrilotriacetic
  • Proteins are eluted with buffer B (buffer A plus 0.3 M imidazole) and c-Met containing fractions are pooled together, loaded onto a Superdex®200 column (Amershan Bioscience, Piscataway, N.J.), eluted with buffer C (40 mM Tris, pH 7.5, 250 mM NaCl, and 10% glycerol).
  • buffer B buffer A plus 0.3 M imidazole
  • c-Met containing fractions are pooled together, loaded onto a Superdex®200 column (Amershan Bioscience, Piscataway, N.J.), eluted with buffer C (40 mM Tris, pH 7.5, 250 mM NaCl, and 10% glycerol).
  • HGF Stimulated Met (pY1349) NCI-H460 Cell-based ELISA
  • NCI-H460 cells (purchased from ATCC) are cultured in RPMI 1640 media (Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS) and plated (prior to becoming 70% confluent) in 96-well flat-bottom plates at a density of 20,000 cells per well in 80 ⁇ L volume. The cells are then incubated overnight in a cell culture incubator (5% CO 2 , 95% Relative Humidity (RH) and 37° C.) and allowed to attach to the plate. The following morning the cells are washed with 2 volumes of a Reduced Serum Media (RSM) (RPMI 1640 media supplemented with 0.5% FBS). After removal of the last wash, 80 ⁇ L of RSM is added to each well of the cell plates.
  • RSM Reduced Serum Media
  • the cell plates are incubated for 2.5 hours in a cell culture incubator, and then dosed with compounds.
  • Compound inhibitors are first solubilized at 10 mM in 100% DMSO and then diluted to 100 ⁇ M with 2% DMSO RSM. Subsequently compound serial dilutions (1:3) are prepared over a 100 ⁇ M to 0.005 ⁇ M range.
  • Cells are dosed with the addition of 20 ⁇ L of compound stock to produce a final DMSO concentration of 0.4% and a final compound concentration dose range between 20 and 0.001 ⁇ M. After dosing with compounds the cells plates are gently agitated to mix and then allowed to incubate for 30 min in a cell culture incubator.
  • the cells are stimulated with the addition of 20 ⁇ L per well of Hepatocyte Growth Factor (HGF) at a final concentration of 100 ng/mL in RSM (all wells except MIN wells are stimulated, MIN wells are dosed with 20 ⁇ L RSM).
  • HGF Hepatocyte Growth Factor
  • the liquid is removed from the cell plate wells, and the cells are lysed by the addition of 50 ⁇ L of ice-cold Meso Scale Discovery® (MSD, Gaithersburg, Md.) 1 ⁇ Lysis Buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, and 1% TRITON® X-100) supplemented with Phosphatase I and II and Protease inhibitors (Sigma, St. Louis, Mo.).
  • MSD Meso Scale Discovery®
  • 1 ⁇ Lysis Buffer 150 mM NaCl, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, and 1% TRITON® X-100
  • the lysates are transferred to and captured on a MSD® Multi-Spot 96-well 4-spot PhosphoMet plate that is BSA-blocked (at 30 mg/mL Block A in 1 ⁇ Tris Wash Buffer) and then washed one time with Tris Wash Buffer. After 2 hours capture (at RT) the lysates are removed from the MSD® plate and the plate is washed with 1X Tris Wash Buffer.
  • MSD® Sulfo-Tag Anti-Total Met antibody
  • MSD® detection antibody
  • 1 ⁇ Tris Wash Buffer supplemented with 10 mg/mL BSA and 0.1% Blocker D-R (MSD®)
  • MSD® Blocker D-R
  • Relative IC 50 values are determined using MSD activity units by calculating percent inhibition with respect to on-plate “MIN” and “MAX” controls and then fitting the percent inhibition values and ten-point dose response data to a four-parameter logistic equation.
  • This assay has a Minimum Significant Ratio (MSR) of 2.06.
  • MSR Minimum Significant Ratio
  • the IC 50 values are less than 0.2 ⁇ M.
  • S114 cells (licensed from PHS, over-express both human HGF and human c-Met) are cultured in a growth media (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal calf serum and expanded. Cells are harvested and washed twice with phosphate buffered saline and 2 ⁇ 10 6 cells are mixed with equal volume of BD MatrigelTM matrix (BD Bioscience, Franklin, N.J.), and injected subcutaneously into the flank of nude mice (athymic nude, from Harlan, Indianapolis, Ind.).
  • a growth media Dulbecco's Modified Eagle Medium
  • compounds formulated in 10% acacia or 1% carboxymethylcellulose/0.5% sodium lauryl sulfate/0.05% antifoam as suspension
  • oral gavage 50 mg/kg.
  • Animals are sacrificed at 2 hours post dose, and tumors are harvested and stored frozen until needed.
  • Frozen tumors are pulverized using motar-pastel.
  • the pulverized tissues are transferred to a tube containing Lysing Matrix D beads (MP Biomedicals, Solon, Ohio) and 600 ⁇ L lysis buffer (RIPA buffer, containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, from Boston Bioproducts).
  • a FastPrep® Cell Disrupter MP Biomedicals
  • Lysates are passed through a 20 gauge needle and transferred to a clean tube. Protein concentration is determined by Bradford method.
  • Tumor lysates are loaded onto MSD® phosphor-Met ELISA plates and phosphor-c-Met level is determined using the same protocol as H460 cell-based ELISA.
  • S114 in vivo inhibition values are equal or greater than 50% at the dose of 50 mg/kg.
  • Example 1 is a potent inhibitor of c-Met phosphorylation with an ED 50 value (dose that produces 50% inhibition in tumor of 2.9 mg/kg, indicating it is a potent c-Met inhibitor in vivo.
  • Human glioblastoma cells U87MG, human gastric cancer cells MKN45, human non small cell lung cancer cells H441, and human renal carcinoma cells Caki-1 are expanded in culture, harvested, and injected subcutaneously onto the rear flank of athymic nude mice.
  • Testing compound is prepared in an appropriate vehicle and is administered by oral gavage when tumors are established (7-21 days after implant). Tumor response is determined by tumor volume measurement performed twice a week during the course of treatment. Tumor volume inhibition (% growth inhibition) is calculated by comparing treated groups to a vehicle control group. Body weight is taken as a general measurement of toxicity.
  • the Compound of Example 1 demonstrates excellent dose dependent anti-tumor activity in these models.
  • Example 1 when dosed at 1.3 mg/kg (oral (PO), bi-daily (BID) ⁇ 35), Example 1 is able to cause 59% growth inhibition of U87MG tumors. At 4 mg/kg dose (PO, BID ⁇ 35), 82% growth inhibition is achieved. At 12 mg/kg dose (PO, BID ⁇ 3 5), 92% growth inhibition reaches.
  • c-Met overexpression is a common feature for many human tumors, including lung, breast, colorectal, gastric, renal, pancreatic, head and neck (1,2).
  • c-Met activating mutations in the kinase domain are implicated as the cause for several tumors, such as hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer (3-7).
  • c-Met inhibitors from Pfizer demonstrated antitumor efficacy in many human xenograft tumors, including U87MG, GTL16, H441, Caki-1, and PC3 (8).
  • the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration.
  • Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al., eds., 19 th ed., Mack Publishing Co., 1995).
  • the compounds of Formula I are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 1 mg to about 200 mg total daily dose, preferably 1 mg to 150 mg total daily dose, more preferably 1 mg to 50 mg total daily dose.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed.
  • the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.

Description

This application claims the priority of U.S. provisional patent application 61/083,294 filed Jul. 24,2008, U.S. provisional patent application 61/085,082 filed Jul. 31, 2008, and U.S. provisional patent application 61/108,659 filed Oct. 27, 2008.
c-Met is a member of the tyrosine kinase growth factor receptor family. c-Met expression occurs in endothelial, epithelial, and mesenchymal cells. Binding to c-Met of the endogenous ligand, hepatocyte growth factor (HGF), promotes cell migration, proliferation, and invasion.
c-Met is implicated in the progression of certain tumors. c-Met overexpression has been shown in numerous tumor types including colon, breast, renal, lung, hemangiomas, squamous cell myeloid leukemia, melanomas, glioblastomas, and astrocytomas. Activation of tumor cell c-Met receptors enhances tumor cell proliferation, invasion/metastasis, and resistance to apoptosis and cytotoxic therapies.
Various amidophenoxyheteroaryl c-Met inhibitors have been reported. See for example, US2005/0288290, US2006/0211695, US2006/0004006, and WO 2007103308.
However, there is still a need for further compounds that inhibit c-Met. The present invention provides novel amidophenoxyindazole compounds believed to have clinical use for treatment of cancer through inhibiting c-Met. Preferred compounds of the present invention are also believed to provide an improvement in potency over certain other c-Met inhibitor compounds found in the art.
The present invention provides compounds of Formula I:
A compound of the formula:
Figure USRE043878-20121225-C00001
wherein:
R1 is H or methyl;
R2 is amino, dimethylamino, fluoro, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazolyl optionally substituted with two methyl substituents, 2-methoxy-pyrimidin-5-yl, 4-methylsulfonylphenyl, tetrahydro-2H-pyran-4-ylamino, (tetrahydro-2H-pyran-4-yl)amino carbonyl, or a morpholin-4-yl substituent:
Figure USRE043878-20121225-C00002
where Ra, Rb and Rc are independently selected from H or methyl;
R3 is H or F;
R4 is H, methyl, piperidin-1-ylmethyl, morpholin-4-ylmethyl, or pyrazol-1-ylmethyl;
R5is H or F; and
X is CH═N, CH═CH, CH═C(CH3), C(CH3)═CH, C(CH3)═N, N(CH3), or C(morpholin-4ylmethyl)═CH C(morpholin-4-ylmethyl)═CH;
or a pharmaceutically acceptable salt thereof.
The present invention provides a method of treating cancer selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
The present invention also provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
This invention also provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use as a medicament. Additionally, this invention provides use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer. In particular these cancers are selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer. Furthermore, this invention provides a pharmaceutical composition for treating cancer selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as an active ingredient.
It will be understood by the skilled reader that most or all of the compounds of the present invention are capable of forming salts. The compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); L. D. Bighley, S. M. Berge, D. C. Monkhouse, in “Encyclopedia of Pharmaceutical Technology’. Eds. J. Swarbrick and J. C. Boylan, Vol. 13, Marcel Dekker, Inc., New York, Basel, Hong Kong 1995, pp. 453-499; S. M. Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, Vol 66, No. 1, January 1977. Preferred pharmaceutically acceptable salts of the compounds of the present invention are the methanesulfonate salts.
Preferred are compounds of Formula I wherein:
(a) R1 is H;
(b) R1 is methyl;
(c) R2 is amino, dimethylamino, cyclopropyl, 6-methyl-pyridin-3-yl, pyrazol-4-yl, or a morpholin-4-yl of the formula:
Figure USRE043878-20121225-C00003
(d) R2 is amino, dimethylamino, pyrazol-4-yl, or morpholin-4-yl;
(e) R2 is pyrazo-4-yl;
(f) R1 is methyl and R2 is pyrazol-4-yl;
(g) R3 is F;
(h) R1 is methyl, R2 is pyrazol-4-yl, and R3 is F;
(i) R4 is H, methyl, or morpholin-4-ylmethyl;
(j) R4is H;
(k) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, and R4 is H;
(l) R5 is H;
(m) R5 is F;
(n) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, and R5 is H;
(o) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, and R5 is F;
(p) X is CH═CH or CH═C(CH3);
(q) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, R5 is H, and X is CH═CH or CH═C(CH3);
(r) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, R5 is F, and X is CH═CH or CH═C(CH3);
(s) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, R5 is H or F, and X is CH═C(CH3);
(t) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, R5 is H, and X is CH═C(CH3); and
(u) R1 is methyl, R2 is pyrazol-4-yl, R3 is F, R4 is H, R5 is F, and X is CH═C(CH3).
The compounds of the present invention can be prepared according to the following synthetic schemes by methods well known and appreciated in the art. Suitable reaction conditions for the steps of these schemes are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Likewise, it will be appreciated by those skilled in the art that synthetic intermediates may be isolated and/or purified by various well known techniques as needed or desired, and that frequently, it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, the skilled artisan will appreciate that in some circumstances, the order in which moieties are introduced is not critical. The particular order of steps required to produce the compounds of the present invention is dependent upon the particular compound being synthesized, the starting compound, and the relative liability of the substituted moieties, as is well appreciated by the skilled chemist. All substituents, unless otherwise indicated, are as previously defined, and all reagents are well known and appreciated in the art.
Compounds of the present invention may be synthesized as illustrated in the following Scheme I, where X, R3, R4, and R5 are as previously defined, and R1′ and R2′ are equal to or precursors of R1 and R2.
Figure USRE043878-20121225-C00004
The compounds of the present invention can be made by standard peptide coupling conditions well known to the skilled artisan. A suitably substituted indazole aniline of formula (a) is reacted with an acid compound of formula (b), in the presence of a peptide coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole hydrate (HOBt), an appropriate base such as N-methylmorpholine, N,N-diisopropylethylamine (DIPEA), or triethylamine (TEA), in a suitable solvent such as dichloromethane (DCM), N,N-dimethylformamide (DMF) or tetrahydrofuran (THF) to provide the desired amide of the present invention. If R1′ is a suitable nitrogen protecting group such as tetrahydropyran (THP), or if R2′ is a functional group protected by a nitrogen-protecting group, a de-protection step is needed to obtain the desired compound of the present invention.
Figure USRE043878-20121225-C00005
The compound of formula (a) can be prepared as illustrated in Scheme II, where R1′, R2′, and R3 are as previously defined.
The compound of formula (f) can react with a properly substituted compound of formula (g) at elevated temperature, in the presence of a suitable base such as sodium bicarbonate in a proper solvent such as DMF to provide the compound of formula (e). The compound of formula (e) can be methylated with a proper methylation reagent such as methyl iodide in a suitable solvent such as THF with a suitable base such as potassium tert-butoxide to provide the compound of formula (d), where R1′ is a methyl. The compound of formula (e) can also be protected with a suitable protecting reagent such as 2,3-dihydropyran (DHP) in a appropriate solvent such as THF, in the presence of an acid such as CH3SO3H to provide the compound of formula (d), where R1′ is a protecting group such as 2-tetrahydropyranyl. [Methods for introducing or removing protecting groups are well known in the art; see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons, New York, (1999)].
The compound of formula (d) can react under various transition-metal facilitated coupling conditions to provide the desired compound of formula (c) with a properly substituted R2′ as previously defined. More specifically, if it is a carbon-carbon coupling, the compound of formula (c) can be made under coupling conditions such as a Suzuki coupling with a suitable boronic acid, an appropriate catalyst such as 1,1′-bis(diphenylphosphino)ferrocene palladium (II) chloride (PdCl2(dppf)), and a proper base such as CsF in a suitable solvent such as 1,4-dioxane at elevated temperature. If it is a carbon-nitrogen coupling, the compound of formula (c) can be made under coupling conditions such as a Buchwald-Hartwig coupling with a proper nitrogen-containing reactant such as morpholine, a suitable ligand such as 2-di-tert-butylphosphino-2′-methylbiphenyl, a base such as KOH, and a catalyst such as tris(dibenzylideneacetone)-dipalladium (0) (Pd2(dba)3), in an appropriate solvent such as tert-butanol at elevated temperature. The coupling reaction can be carried out under conventional heating conditions or under microwave reaction conditions well known to the skilled artisan.
The compound of formula (c) can be reduced to an amino compound under various reduction conditions well known to the skilled artisan. More specifically, the compound of formula (c) can react with stannous chloride in a suitable solvent such as ethyl acetate (EtOAc)/ethanol (EtOH) at an elevated temperature to give the desired compound of formula (a). If R1′ is a nitrogen-protecting group such as 2-tetrohydropyranyl, the protecting group will be cleaved. R1′ will be a proton after the reduction.
The compound of formula (c) can also be reduced by reacting with N,N-dimethylhydrazine and FeCl3 in a proper solvent such as methanol (MeOH), or H2/palladium on carbon (Pd/C) in proper solvent such as EtOH. Both reduction conditions will only reduce the nitro group to an amino group, and will leave the nitrogen-protecting group, R1′, untouched.
It is well known to the skilled artisan that reactions on nitrogen of some nitrogen-containing heterocycles such as indazole compounds could generate tautomers. The ratio of tautomers depends essentially on the mode of performing reactions and different conditions. Intermediates disclosed in this invention with nitrogen protecting groups such as THP may exist as regioisomers. In the compounds of the present invention, when R1 is a proton, it may exist as a pair of fast exchanging tautomers as illustrated in Scheme III.
Figure USRE043878-20121225-C00006
The following preparations and examples are named using ChemDraw® Ultra version 10.0.
Preparation 1 N-(4-Methoxy-2-methylphenyl)acetamide
To a solution of 4-methoxy-2-methylaniline (120 g, 0.88 mol) in DCM (400 mL) is added acetic acid anhydride (120 mL, 1.2 mol) dropwise. The reaction mixture is stirred at room temperature (RT) for 3 hours. After petroleum ether (PE) (1.6 L) is added, the slurry is stirred for another one hour. The precipitate is collected by filtration and is washed with PE to give the product as a pink solid (130 g, 82% yield). MS (m/z): 180.0 (M+H).
Preparation 2 N-(5-Bromo-4-methoxy-2-methylphenyl)acetamide
To a solution of N-(4-methoxy-2-methylphenyl)acetamide (130 g, 0.73 mol) in acetic acid (800 mL) is added bromine (42 mL, 0.8 mol) dropwise at 0° C. After addition, the resulting mixture is stirred at RT overnight. Saturated aqueous NaHSO3 is added until a clear solution is obtained, and then a large amount of water (2.0 L) is added forming a precipitate. The precipitated solid is collected and washed with water to give the crude product (thin layer chromatography (TLC) solvent: DCM:EtOAc=10:1). The solid is dissolved in minimum amount of refluxing DCM, and then PE (about 10-20% volume of DCM used) is added. The resulting solution is cooled to RT. After 2 hours, the precipitated solid is collected and washed with PE to give a white product (108 g, 57% yield). MS (m/z): 260.0 (M+H).
Preparation 3 5-Bromo-4-methoxy-2-methylaniline
To a solution of N-(5-bromo-4-methoxy-2-methylphenyl)acetamide (108 g, 0.42 mol) in MeOH (400 mL) is added concentrated HCl (160 mL, 2 mol). After being heated at reflux overnight, the mixture is neutralized with aqueous NaHCO3, and extracted with EtOAc (1200 mL). The organic phase is dried and concentrated to afford the product (76 g, 84% yield). MS (m/z): 216.0 (M+H).
Preparation 4 1-(5-Bromo-4-methoxy-2-methylphenyl)diazonium tetrafluoroborate
To a solution of 5-bromo-4-methoxy-2-methylaniline (76 g, 0.35 mol) in HBF4 (48% wt, 140 mL) and H2O (280 mL) is added a solution of NaNO2 (27.6 g, 0.4 mol) in H2O (60 mL) at 0° C. After the addition is completed, the reaction mixture is stirred at 0° C. for 30 minutes (min). The precipitate is filtered, washed with a small amount of ice water several times and dried to give the product (110 g, 99% yield). MS (m/z): 229.0 (M+H).
Preparation 5 6-Bromo-5-methoxy-1H-indazole
1-(5-Bromo-4-methoxy-2-methylphenyl)diazonium tetrafluoroborate (110 g, 0.35 mol) is added in one portion to a stirred mixture of KOAc (140.5 g, 1.43 mol) and 18-crown-6-ether (9.3 g, 0.035 mol) in CHCl3 (800 mL) and stirred at RT overnight. The mixture is filtered and the solid is washed with DCM. The combined filtrate is concentrated and the residue is purified by silica gel column chromatography (DCM:MeOH=50:1) to give the product (10 g). The cake is added to THF (1600 mL) and the mixture is stirred at RT for one hour. The mixture is filtered and the filtrate is concentrated to give 10 g of the crude product (total yield 88%). MS (m/z): 229.0 (M+H).
Preparation 6 6-Bromo-5-hydroxy-1H-indazole
To a solution of 6-bromo-5-methoxy-1H-indazole (60 g, 0.265 mol) in DCM (1300 mL) is added a solution of BBr3 (105 g, 0.42 mol) in DCM (200 mL) at 0° C. The reaction mixture is warmed to RT and stirred overnight. Then the reaction solution is quenched with MeOH at 0° C. The solvent is removed in vacuo and the residue is neutralized with NaHCO3 solid. The mixture is partitioned by water (1500 mL) and EtOAc (1500 mL). The aqueous layer is extracted with EtOAc (1500 mL) two times. The combined organic layers are dried and concentrated to give crude product, which is purified by silica gel column chromatography (PE:THF=2:1) to give the desired product (42.5 g, 75% yield). MS (m/z): 215.0 (M+H).
Preparation 7 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole
A mixture of 6-bromo-5-hydroxy-1H-indazole (7.0 g, 33.0 mmol), 3,4-difluoronitrobenzene (4.98 mg, 31.0 mmol), NaHCO3 (2.5 g, 31.0 mmol) in DMF (100 mL) is stirred at 80° C. for 4 hours. Then LiCl (10% aqueous solution) is added and the solution is extracted with EtOAc. The organic phase is dried over anhydrous MgSO4, filtered and concentrated. The residue is purified by silica gel column chromatography eluting with PE:DCM (1:1) to give the desired product (5.5 g, 46.6% yield). MS (m/z): 354.0 (M+H).
The following compound is prepared essentially by the method of Preparation 7:
Prep. Physical data
No. Chemical name MS (m/z) (M + H)
8 6-Bromo-5-(4-nitrophenoxy)-1H-indazole 336
Preparation 9 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
To a solution of 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole (5.0 g, 14.2 mmol) in THF (50 mL) is added DHP (2.4 g, 28.5 mmol) and CH3SO3H (1.0 g, 10.4 mmol). The resulting mixture is stirred at RT for 1 hour. Then EtOAc and aqueous NaHCO3 solutions are added. The organic phase is separated, dried over anhydrous MgSO4, filtered and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (5:1) to give the desired product (5.5 g, 89.0% yield). MS (m/z): 436.0 (M+H).
The following compound is prepared essentially by the method of Preparation 9:
Prep. Physical data
No. Chemical name MS (m/z) (M + H)
10 6-Bromo-5-(4-nitrophenoxy)-1-(tetrahydro- 418.0
2H-pyran-2-yl)-1H-indazole
Preparation 11 6-Bromo-1-methyl-5-(4-nitrophenoxy)-1H-indazole
To a mixture of 6-bromo-5-(4-nitrophenoxy)-1H-indazole (2.68 g, 8.02 mmol) and KOH (600 mg, 10.69 mmol) in acetone (100 mL) cooled with an ice-water bath is added dropwise methyl iodide (0.55 mL, 8.83 mmol). After the reaction mixture is stirred at 0° C. for 2 hours, it is stirred at RT overnight. The solvent is removed, and the residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the product (1.50 g, 53.7% yield). MS (m/z): 348.0 (M+H).
The following compound is prepared essentially by the method of Preparation 11:
Prep. Physical data
No. Chemical name MS (m/z) (M + H)
12 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-1- 365.9
methyl-1H-iadazole
Alternatively, 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole (Preparation 12) may also be prepared in the following 3 step process:
2,4-Dibromo-5-hydroxy-benzaldehyde (50 g, 178.6 mmol), 1,2-difluoro-4-nitrobenzene (28.4 g, 178.6 mmol) and potassium carbonate (49.0 g, 357.2 mmol) are stirred in DMF (500 mL) at 60° C. for 2 hours. The reaction is quenched with water (1000 mL) and extracted with methyl tert-butylether (MTBE) (2×500 mL). The organic layer is washed with saturated sodium chloride aqueous solution (2×500 mL), dried with anhydrous sodium sulfate, and concentrated to obtain a yellow solid. The crude solid is recrystallized in EtOAc/PE (1:5) to give 2,4-dibromo-5-(2-fluoro-4-nitrophenoxy)benzaldehyde as a yellow solid (52.8 g, 70.6% yield).
2,4-Dibromo-5-(2-fluoro-4-nitrophenoxy)benzaldehyde (13.0 g, 31.0 mmol) is refluxed with methylhydrazine (4.3 g, 93 mmol) in THF (130 mL) for 2 hours. The reaction is quenched with water (150 mL) and extracted with MTBE (2×150 mL). The organic layer is washed with saturated sodium chloride aqueous solution (2×150 mL), dried with anhydrous sodium sulfate, and concentrated to obtain a solid. The crude solid is recrystallized in EtOAc/hexane to obtain 1-(2,4-dibromo-5-(2-fluoro-4-nitrophenoxy)benzylidene)-2-methylhydrazine as a yellow solid (10.6 g, 76.7% yield). MS (m/z): 447.9 (M+H).
1-(2,4-Dibromo-5-(2-fluoro-4-nitrophenoxy)benzylidene)-2-methylhydrazine (1.0 g, 2.2 mmol), cuprous chloride (22 mg, 0.2 mmol), potassium carbonate (0.638 g, 7.2 mmol), DMF (10 mL), and a stir bar are combined in a pressure tube under nitrogen. The cap is sealed and the tube is placed in an oil bath with stirring. The bath is heated to 100° C. over 30 min and held at 100° C. for 6 hours and then cooled to RT. The reaction mixture is poured into a separatory funnel containing MTBE (10 mL) and water (10 mL). The layers are separated and the aqueous layer is extracted with an additional portion of MTBE (10 mL). The organic layers are combined, and washed with water followed by saturated sodium chloride aqueous solution. The organic layer is dried over magnesium sulfate and concentrated to yield 0.70 g of crude product. The crude solid is dissolved in DCM and heptane, and then concentrated to remove DCM resulting in the formation of a slurry. The product is collected by filtration and dried under vacuum to give 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole as a solid (0.65 g, 79% yield). MS (m/z): 367.8 (M+H).
Preparation 13 6-Bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-ol
To a solution of 6-bromo-5-hydroxy-1H-indazole (725.0 g, 3.4 mol) in THF (10.2 L) is added DHP (336.5 mL, 3.57 mol) and CH3SO3H (65.4 g, 0.68 mol) at RT. The resulting mixture is stirred at RT for 22 hours. The reaction mixture is quenched with distilled water (6 L) and extracted with EtOAc (6 L). Saturated aqueous NaHCO3 solution (1100 mL) is added to adjust the pH to 8. After phase separation, the organic phase is washed with water (4 L) and then saturated aqueous sodium chloride (3 L), dried over anhydrous Na2SO4, filtered, and concentrated to give the product as a solid (1.64 kg, 99.3% yield). MS (m/z): 299.0 (M+H).
Preparation 14 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole
To a solution of 6-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-ol (1.475 kg, 4.96 mol) in DMF (5.3 L) is added 3,4-difluoronitrobenzene (1.18 kg, 7.45 mol) and NaHCO3 (625.5 g, 7.45 mol) at RT. The reaction mixture is heated at 70° C. for 10 hours and then cooled to less than 20° C. Deionized (DI) water (7.9 L) is slowly added to the solution and the resulting slurry is stirred at 15° C. for one hour. The solid is collected by vacuum filtration, and the solid cake is washed with water (8 L). It is then air dried under vacuum on filter and is triturated with methyl MTBE (18.6 L) at reflux conditions for two hours. The slurry is then cooled to RT and the solid is collected by vacuum filtration. The solid cake is washed with MTBE (4 L×2) and dried in a vacuum oven at 35° C. to give the desired product (1.405 kg, 64.9% yield). MS (m/z): 436.0 (M+H).
Preparation 15 5-(2-Fluoro-4-nitrophenoxy)-6-(pyridine-4-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
A mixture of 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (5.0 g, 11.5 mmol), 4-pyridineboronic acid (3.0 g, 24.3 mmol), PdCl2(dppf) (1.8 g, 2.25 mmol) and CsF (5.0 g, 33.0 mmol) in 1,4-dioxane (100 mL) is stirred at 110° C. overnight. Then, aqueous NH4Cl and EtOAc are added. The organic phase is separated, dried over anhydrous MgSO4 and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the desired product (2.8 g, 56% yield). MS (m/z): 435.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 15:
Physical
data
MS (m/z)
Prep. No. Chemical name (M + H)
16 5-(2-Fluoro-4-nitrophenoxy)-6-(4-(methyl- 512.1
sulfonyl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-
1H-indazole
17 tert-Butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1- 524.1
(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-1H-
pyrazole-1-carboxylate
5-(2-Fluoro-4-nitrophenoxy)-6-(1H-pyrazol-4-yl)-1- 424.1
(tetrahydro-2H-pyran-2-yl)-1H-indazole
18 5-(2-Fluoro-4-nitrophenoxy)-6-(pyridin-3-yl)-1- 435.1
(tetrahydro-2H- pyran-2-yl)-1H-indazole
19 6-(1,3-Dimethyl-1H-pyrazol-5-yl)-5-(2-fluoro-4- 452.1
nitrophenoxy)-1-(tetrahydropyran-2-yl)-1H-indazole
20 5-(2-Fluoro-4-nitrophenoxy)-6-(2-methoxypyrimi- 466.1
din-5-yl)-1-(tetrahydropyran-2-yl)-1H-indazole
21 5-(2-Fluoro-4-nitrophenoxy)-6-(2-methylpyridin-4- 449.1
yl)-1-(tetrahydropyran-2-yl)-1H-indazole
 22* 6-Cyclopropyl-5-(2-fluoro-4-nitrophenoxy)-2- 398
(tetrahydro-2H-pyran-2-yl)-2H-indazole
23 tert-Butyl 4-(1-methyl-5-(4-nitrophenoxy)-1H- 436.0
indazol-6-yl)-1H-pyrazole-1-carboxylate
1-Methyl-5-(4-nitrophenoxy)-6-(1H-pyrazol-4-yl)- 336.0
1H-indazole
24 5-(2-Fluoro-4-nitrophenoxy)-1-methyl-6-(2- 379.1
methylpyridin-4-yl)-1H-indazole
25 5-(2-Fluoro-4-nitrophenoxy)-1-methyl-6-(pyridin-3- 365.1
yl)-1H-indazole
26 (tert-Butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl- 454.0
1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
27 tert-Butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl- 454.1
1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
5-(2-Fluoro-4-nitrophenoxy)-1-methyl-6-(1H- 354.1
pyrazo1-4-yl)-1H-indazole
*Reaction is carried out under microwave conditions at 95° C. for about 90 min.
Preparation 28 6-(2,6-Dimethylpyridin-4-yl)-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydropyran-2-yl)-1H-indazole
To a solution of 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydropyran-2-yl)-1 1H-indazole (1.31 g, 3.0 mmol) in 1,4-dioxane (20 mL) is added bis(pinacolato)diboron (0.91 g, 3.6 mmol), Pd2(dba)3 (0.14 g, 0.2 mmol), tricyclohexylphosphine (0.1 g, 0.4 mmol), potassium acetate (KOAc) (0.59 g, 6.0 mmol) under N2. After the reaction mixture is heated to reflux for 3 hours under N2, it is cooled to RT. 4-Bromo-2,6-dimethylpyridine hydrobromide (0.8 g, 3.0 mmol), PdCl2(dppf) (0. 16 g, 0.2 mmol), CsF (1.38 g, 9.0 mmol) are added under N2. The resulting mixture is heated at reflux overnight under N2. The solid is filtered off and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (from 5:1 to 1:1) to give the product (0.67 g, 48.3% yield). MS (m/z): 463.1 (M+H).
Preparation 29 4-(5-(2-Fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)morpholine
To a solution of 6-bromo-5-(2-fluoro-4-nitro-phenoxy)-1-(tetrahydropyran-2-yl)-1 H-indazole (8.0 g, 18 mmol) in tert-butanol (150 mL) and H2O (3.2 mL) is added Pd2(dba)3 (320 mg, 0.35 mmol), 2-di-tert-butylphosphino-2′-methylbiphenyl (480 mg, 1.54 mmol), KOH (3.2 g, 57 mmol) and morpholine (3.2 g, 36.7 mmol) under N2. After the mixture is stirred at 70° C. for 2 hours under a N2 atmosphere, it is filtered and the filtrate is concentrated. The residue is partitioned with EtOAc (100 mL) and saturated aqueous NH4Cl (30 mL). The organic layer is separated, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the product (4.5 g, 56.5% yield). MS (m/z): 443.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 29:
Physical
data
Prep. MS (m/z)
No. Chemical name (M + H)
30 5-(2-Fluoro-4-nitrophenoxy)-N,N-dimethyl-1- 401.2
(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine
31 N,N-Dimethyl-5-(4-nitrophenoxy)-1-(tetrahydro- 383.1
2H-pyran-2-yl)-1H-indazol-6-amine
Preparation 32 4-(5-(2-Fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H -indazol-6-yl)-2-methylmorpholine(racemic)
To a 25 mL microwave vial is added 6-bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (0.8 g, 1.8 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98 mg, 165 μmol) and Pd2(dba)3 (50 mg, 55 μmol). The mixture is suspended in toluene (12 mL, 113 mmol) and then 2-methylmorpholine hydrochloride (278 mg, 2.02 mmol) and sodium tert-butoxide (454 mg, 4.58 mmol) are added. The reaction mixture is heated at 150° C. for 25 min in a microwave reactor. The reaction mixture is then concentrated and the residue is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 90% (A): 10%(B) to 60%(A):40%(B) over 60 min then to 50%(A):50%(B) for 20 min to give an orange solid as the desired product (410 mg, 39% yield). MS (m/z): 457 (M+H).
The following compounds are prepared essentiallyby the method of Preparation 32:
Physical
data
Prep. MS (m/z)
No. Chemical name (M + H)
33 (2R)-4-(5-(2-Fluoro-4-nitrophenoxy)-2-(tetrahydro-2H- 456.8
pyran-2-yl)-2H-indazol-6-yl)-2-methyhmorpholine
34 (2S,6R)-4-(5-(2-Fluoro-4-nitrophenoxy)-2-(tetrahydro- 470.8
2H-pyran-2-yl)-2H-indazol-6-yl)-2,6-
dimethylmorpholine
Preparation 35 4-(5-(2-Fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-6-yl)-2,2-dimethylmorpholine
6-Bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (1.5 g, 3.4 mmol) is added to a 50 mL Genevac Carousel® tube and is suspended into the amylene hydrate (10 mL, 91.4 mmol) and N2 is bubbled in suspension. To the mixture is added 2-(di-tert-butylphosphino)-2′-methylbiphenyl (97.7 mg, 309 μmol), Pd2(dba)3 (94.5 mg, 103 μmol) and DI water (0.3 mL), and N2 bubbling is continued for 10 min. To this mixture is added 2,2-dimethylmorpholine hydrochloride (1.04 g, 6.9 mmol) and a solution of KOH (617 mg, 11.0 mmol) dissolved in 0.3 mL of distilled water. The reaction mixture is heated at 80° C. for 2 hours and then cooled to RT. The mixture is then poured into EtOAc (300 mL), washed with distilled water (1×100 mL) and then saturated aqueous sodium chloride (100 mL). The combined aqueous layers are extracted with EtOAc (100 mL). The combined organic solution is dried with Na2SO4, filtered, and concentrated to dryness to give a gold solid. The solid is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 95%(A):5%(B) to 75%(A):25%(B) over 70 min to give a light yellow solid as the desired product (410 mg, 25% yield). MS (m/z): 470.8 (M+H).
Preparation 36 5-(2-Fluoro-4-nitrophenoxy)-6-(pyridine-4-yl)-1H-indazole
To a solution of 5-(2-fluoro-4-nitrophenoxy)-6-(pyridine-4-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.8 g, 6.45 mmol) in EtOH (30 mL) is added HCl (concentrated 5.0 mL). The mixture is stirred at 80° C. for 2 hours. Then aqueous NaHCO3 and EtOAc are added. The organic phase is dried over anhydrous MgSO4 and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the desired product (1.95 g, 86.0% yield). MS (m/z): 351.0 (M+H).
Preparation 37 3-Fluoro-4-(6-(pyridine-4-yl)-1H-indazole-5-yloxy)aniline
A mixture of 5-(2-fluoro-4-nitrophenoxy)-6-(pyridine-4-yl)-1H-indazole (1.95 g, 4.5 mmol) and SnCl2.2H2O (10.2 g, 45.3 mmol) in EtOAc/EtOH (200 mL/10 mL) is stirred at 80° C. for 2 hours. Then aqueous NaHCO3 and EtOAc are added. The organic phase is dried over anhydrous MgSO4 and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (2:1) to give the desired product (1.10 g, 61.0% yield). MS (m/z): 321.0 (M+H).
Preparation 38 3-Fluoro-4-(6-(4-(methylsulfonyl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yloxy)aniline
To a solution of 5-(2-fluoro-4-nitrophenoxy)-6-(4-(methylsulfonyl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (320 mg, 0.63 mmol) in EtOAc (50 mL) is added Pd/C (10%, 100 mg). The resulting mixture is degassed by evacuation and backfilled with H2 three times. It is stirred under an atmosphere of H2 at RT overnight. The solid is removed by filtration and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (20:1) to give the desired product (250 mg, 83% yield). MS (m/z): 482.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 38:
Physical
data
Prep. MS (m/z)
No. Chemical name (M + H)
39 3-Fluoro-4-(1-methyl-6-(2-methylpyridin-4-yl)-1H- 349.1
indazol-5-yloxy)aniline
40 tert-Butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl- 424
1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
Preparation 41 4-(6-(1H-Pyrazol-4-yl)-1H-indazol-5-yloxy)-3-fluoroaniline
To a solution of 5-(2-fluoro-4-nitrophenoxy)-6-(1H-pyrazol-4-yl)-1-(tetrahydropyran-2-yl)-1H-indazole (900 mg, 2.13 mmol) and 4-[5-(2-fluoro-4-nitro-phenoxy)-1-(tetrahydropyran-2-yl)-1H-indazol-6-yl]-pyrazole-1-carboxylic acid tert-butyl ester (3.1 g, 5.92 mmol) in EtOAc/EtOH (75 mL/75 mL) is added stannous chloride dihydrate (10 g, 52.74 mmol). The reaction mixture is stirred at reflux overnight. After it is cooled and basified with saturated aqueous NaHCO3 to pH 8-9, the mixture is extracted with EtOAc (100 mL). The organic phase is separated, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting first with PE:EtOAc (1:1) and then with EtOAc to give the product (1.75 g, 71.0% yield). MS (m/z): 310.0 (M+H).
The following compounds are prepared essentially by the method of Preparation 41:
Physical data
Prep. MS (m/z)
No. Chemical name (M + H)
42 3-Fluoro-4-(6-(pyridin-3-yl)-1H-indazol-5- 321.1
yloxy)aniline
43 4-(6-(1,3-Dimethyl-1H-pyrazol-5-yl)-1H-indazol-5- 338.1
yloxy)-3- fluoroaniline
44 3-Fluoro-4-(6-morpholino-1H-indazol-5-yloxy)aniline 329.1
45 4-[6-(2,6-Dimethylpyridin-4-yl)-1H-indazol-5-yloxy]- 349.1
3-fluoroaniline
46 3-Fluoro-4-[6-(2-methoxypyrimidin-5-yl)-1H- 352.1
indazol-5-yloxy]-aniline
47 5-(4-Amino-2-fluorophenoxy)-N,N-dimethyl-1H- 287.1
indazol-6-amine
48 3-Fluoro-4-(6-(2-methylpyridin-4-yl)-1H-indazol-5- 335.1
yloxy)aniline
49 5-(4-Aminophenoxy)-N,N-dimethyl-1H-indazol-6- 269.1
amine
50 4-(1-Methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5- 306.0
yloxy)aniline
51 3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H- 324.1
indazol-5-yloxy)aniline
52 3-Fluoro-4-(1-methyl-6-(pyridin-3-yl)-1H-indazol-5- 335.1
yloxy)aniline
Preparation 53 4-(6-Cyclopropyl-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-yloxy)-3-fluoroaniline
To a 25 mL glass vial is added 6-cyclopropyl-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (395 mg, 994 μmol) and MeOH (20 mL, 494 mmol). To the suspension is added N,N-dimethylhydrazine (756 μL, 9.94 mmol) and FeCl3 (163 mg, 994 μmol). The vial is capped, and heated to 60° C. and stirred for 2 hours and then stirred at 50° C. overnight. The mixture is filtered over a Buchner funnel and the solid washed with MeOH (100 mL). The filtrate is collected and concentrated to give a brown/orange solid. The residue is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in a DCM solution (B), gradient from 100% (A) to 85%(A): 15%(B) over 50 min to give a yellow solid as the title compound (358 mg, 98% yield). MS (m/z): 368 (M+H).
The following compounds are prepared essentially by the method of Preparation 53:
Physical
data
Prep. MS (m/z)
No. Chemical name (M + H)
54 3-Fluoro-4-(6-(2-methylmorpholino)-2-(tetrahydro-2H- 427
pyran- 2-yl)-2H-indazol-5-yloxy)aniline
55 4-(6-(2,2-Dimethylmorpholino)-2-(tetrahydro-2H- 441
pyran-2-yl)-2H-indazol-5-yloxy)-3-fluoroaniline
56 3-Fluoro-4-(6-((R)-2-methylmorpholino)-2-(tetrahydro- 427
2H-pyran-2-yl)-2H-indazol-5-yloxy)aniline
57 4-(6-((2S,6R)-2,6-dimethylmorpholimo)-2-(tetrahydro- 441
2H-pyran-2-yl)-2H-indazol-5-yloxy)-3-fluoroaniline
58 3-Fluoro-4-(6-morpholino-2-(tetrahydro-2H-pyran-2- 413
yl)-2H- indazol-5-yloxy)aniline
Preparation 59 N-(Diphenylmethylene)-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-amine
To a 10 mL microwave vial is added 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole (500 mg, 1.37 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (73 mg, 123 μmol) and Pd2(dba)3 (38 mg, 41 μmol). The mixture is suspended in toluene (5 mL, 47 mmol) and benzophenone imine (272 mg, 1.5 mmol) and sodium tert-butoxide (203 mg, 2.05 mmol) are added. The mixture is heated at 150° C. for 20 min in a microwave reactor. After cooling, the reaction solution is concentrated to give a brown oil which is dissolved in DCM (150 mL) and washed with saturated aqueous sodium chloride (2×50 mL). The aqueous layers are combined and extracted with DCM (1×50 mL), dried with Na2SO4, filtered and concentrated to give a brown residue. The residue is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 85%(A): 15%(B) to 50%(A):50%(B) over 50 min to give a yellow solid material as the title compound (574 mg, 90.1% yield). MS (m/z): 467.2 (M+H).
Preparation 60 5-(4-Amino-2-fluorophenoxy)-N-benzhydryl-1-methyl-1H-indazol-6-amine
To a 100 mL round bottom flask is added N-(diphenylmethylene)-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-amine (424 mg, 909 μmol) and EtOH (35 mL, 601 mmol). To the mixture is added ammonium formate (1000 mg, 15.9 mmol) followed by the addition of 10% Pd/C (300 mg, 141 μmol) and the reaction mixture is stirred at RT for 1 hour and heated at 45° C. for 15 min. The solvent is removed and the residue is dissolved in DCM (150 mL) and distilled water (100 mL). The organic layer is washed with distilled water (1 x 100 mL), and the combined aqueous layers are extracted with DCM (1 x 50 mL). The combined organic solution is dried with Na2SO4, filtered, and concentrated. The crude is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 90% (A)10% (B) to 40% (A):60% (B) over 90 min to give an off-white solid material as the title compound (204 mg, 51% yield). MS (m/z): 438.8 (M+H).
Preparation 61 1-Acetyl-6-bromo-1H-indazol-5-yl acetate
A mixture of 6-bromo-5-hydroxy-1H-indazole (25 g, 117 mmol) in acetic acid anhydride (75 mL) is heated at 110° C. with stirring for 2 hours. After it is cooled, diethyl ether (100 mL) is added. The precipitate is collected by filtration, washed with diethyl ether (30 mL), and dried under vacuum to afford the product (34 g, 98% yield). MS (m/z): 297.0 (M+H).
Preparation 62 Ethyl 5-hydroxy-1H-indazole-6-carboxylate
An autoclave is charged with 1-acetyl-6-bromo-1H-indazol-5-yl acetate (25 g, 84 mmol), TEA (25 g, 252 mmol), dichloro bis (benzonitrile) palladium (Pd(PhCN)2Cl2) (1.6 g, 4.2 mmol), 1,1 ′-bis(diphenylphosphino)ferrocene (dppf) (4.7 g, 8.4 mmol) and EtOH (500 mL) is stirred at 130° C. under an atmosphere of CO for 8 hours. The reaction mixture is concentrated, and the residue is purified by silica gel column chromatography to afford the product (15.5 g, 90% yield). MS (m/z): 207.0 (M+H).
Preparation 63 Ethyl 5-hydroxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate
To a solution of ethyl 5-hydroxy-1H-indazole-6-carboxylate (15.5 g, 75 mmol) in DCM (100 mL) and THF (100 mL) containing methanesulfonic acid (721 mg, 7.5 mmol) is added a solution of 3,4-dihydro-2H-pyran (6.6 g, 79 mmol) in DCM (20 mL) dropwise at RT. The resulting solution is stirred at RT overnight. After the solvent is removed, EtOAc (500 mL), saturated aqueous sodium chloride (500 mL) and NaHCO3 (5 g) are added. The organic layer is separated, dried and concentrated. The residue is purified by silica gel column chromatography to afford the product (16.8 g, 77% yield). MS (m/z): 291.1 (M+H).
Preparation 64 Ethyl-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate
A mixture of ethyl 5-hydroxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (10.8 g, 37 mmol), 1,2-difluoro-4-nitrobenzene (7.1 g, 44 mmol), NaHCO3 (7.4 g, 88 mmol) and DMF (100 mL) is stirred at 80° C. for 2 hours. After it is cooled to RT, water (400 mL) and PE (50 mL) are added and the mixture is stirred for 20 min. The precipitate is collected and dried under vacuum at 50° C. to afford the product (15 g, 95% yield). MS (m/z): 430.1 (M+H).
Preparation 65 5-(2-Fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylic acid
To a solution of ethyl-5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (22 g, 51.2 mmol) in THF (60 mL) and MeOH (60 mL) and H2O (10 mL) is added LiOH (3 g, 125 mmol). The resulting solution is stirred at RT for 1.5 hours and the organic solvents are removed. The aqueous residue is acidified with cold 6N HCl to pH 2, and extracted with EtOAc (150 mL). The organic phase is separated, dried, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc:acetic acid (100:100:1) to afford the product (19.5 g, 95% yield). MS (m/z): 402.1 (M+H).
Preparation 66 tert-Butyl 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylcarbamate
A mixture of 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylic acid(590 mg, 1.47 mmol), diphenylphosphoryl azide (485 mg, 1.76 mmol), TEA (179 mg, 1.76 mmol), 4 Å molecular sieves (3 g) in tert-butanol (40 mL) is stirred at 80° C. overnight. The mixture is filtered and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with PE/EtOAc (10:1) to give the desired product (400 mg, 65% yield). MS (m/z): 473.1 (M+H).
Preparation 67 tert-Butyl 5-(4-amino-2-fluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylcarbamate
To a solution of tert-butyl 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylcarbamate (400 mg, 0.85 mmol) in EtOAc (50 mL) is added Pd/C (10%, 50 mg). The resulting mixture is degassed by evacuation and backfilled with H2 three times. The mixture is stirred under an atmosphere of H2 at RT overnight. The solid is removed by filtration and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (10:1) to give the desired product (300 mg, 80% yield). MS (m/z): 443.2 (M+H).
Preparation 68 5-(2-Fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazole-6-carboxamide
The solution of 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylic acid (0.5 g, 1.25 mmol), tetrahydropyran-4-ylamine (0.13 g, 1.25 mmol), EDCI (0.24 g, 1.25 mmol), HOBT (0.17 g, 1.25 mmol), N-methylmorpholine (0.5 mL) in DMF (5 mL) is stirred at RT overnight. Then the reaction mixture is partitioned with saturated aqueous NH4Cl (20 mL) and EtOAc (50 mL). The organic phase is separated, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (1:1) to provide the product (0.49 g, 81.2% yield). MS (m/z): 485.1 (M+H).
Preparation 69 5-(4-Amino-2-fluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazole-6-carboxamide
To a solution of 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazole-6-carboxamide (0.49 g, 1.0 mmol) in MeOH (50 mL) is added Pd/C (100 mg, 10% wt) under N2. The resulting mixture is degassed by evacuation and backfilled with nitrogen. Then the reaction mixture is stirred at RT under H2 atmosphere overnight. The solid is removed by filtration and the filtrate is concentrated to give a crude product (0.42 g, 91.4% yield). MS (m/z): 455.1 (M+H).
Preparation 70 5-(Benzyloxy)-6-bromo-1H-indazole
To a solution of 6-bromo-5-hydroxy-1H-indazole (5 g, 23.5 mmol) in THF (50 mL) is added benzyl alcohol (3.05 g, 28.2 mmol), PPh3 (7.39 g, 28.2 mmol) and diethylazodicarboxylate (4.46 mL, 28.2 mmol). After the reaction mixture is stirred at RT overnight, EtOAc (50 mL) and saturated aqueous NH4Cl (30 mL) are added. The organic phase is separated, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (4:1) to provide the product (5.0 g, 70.2% yield). MS (m/z): 303.0 (M+H).
Preparation 71 5-(Benzyloxy)-6-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
To a solution of 5-(benzyloxy)-6-bromo-1H-indazole (5 g, 16.5 mmol) in THF (30 mL) and DCM (30 mL) is added 3,4-dihydro-2H-pyran (3 mL, 32.8 mmol) and methanesulfonic acid (1 mL, 15.3 mmol). After the reaction mixture is stirred at RT for 2 hours, EtOAc (50 mL) and saturated aqueous NaHCO3 are added. The organic phase is separated, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (4:1) to give the desired product (2.7 g, 42.2% yield). MS (m/z): 387.0 (M+H).
Preparation 72 5-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazol-6-amine
To a solution of 5-(benzyloxy)-6-brome-1-(tetrahydri-2H-pyran-2-yl)-1H-indazole (2 g, 5.16 mmol) in toluene (30 mL) is added tetrahydropyran-4-ylamine (800 mg, 7.91 mmol), palladium acetate (60 mg, 267 μmol), 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (200 mg, 508 μmol) and sodium tert-butoxide (700 mg, 7.28 mmol) under N2. After the reaction is stirred at 100° C. under N2 for 1 hour, EtOAc (30 mL) is added and the reaction mixture is filtered. The filtrate is concentrated and the residue is purified by silica gel column chromatography eluting first with EtOAc:PE (1/1) and then EtOAc to give the desired product (1.87 g, 88.8% yield). MS (m/z): 408.2 (M+H).
Preparation 73 N-(5-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)acetamide
To a solution of 5-(benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazol-6-amine (1.87 g, 4.59 mmol) in THF (30 mL) is added acetyl chloride (0.39 mL, 5.48 mmol) and K2CO3 (760 mg, 5.50 mmol). After the reaction mixture is heated to reflux for 30 min, H2O (20 mL) and EtOAc (30 mL) are added. The organic phase is separated, washed with saturated aqueous NH4Cl, dried and concentrated to give the product (1.7 g, 82.4% yield). MS (m/z): 450.2 (M+H).
Preparation 74 N-(5-Hydroxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)acetamide
To a solution of N-(5-(benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)acetamide (1.7 g, 3.78 mmol) in EtOH (100 mL) and EtOAc (100 mL) is added Pd/C (1 g, 10% wt). After the reaction mixture is stirred at RT under H2 overnight, it is filtered and the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting first with PE:EtOAc (1:1) and then EtOAc to give the product (1.2 g, 88.2% yield). MS (m/z): 360.2 (M+H).
Preparation 75 N-(5-(2-Fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)acetamide
To a solution of N-(5-hydroxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-tetrahydro-2H-pyran-4-yl)acetamide (1.2 g, 3.34 mmol) in DMF (30 mL)is added 1,2-difluoro-4-nitrobenzene (0.64 g, 4.02 mmol) and Cs2CO3 (1.63 g, 5.00 mmol). After the reaction mixture is stirred at 100° C. for 2 hours, EtOAc (60 mL) and saturated aqueous NH4Cl are added. The organic phase is separated, dried over MgSO4 and concentrated. The residue is purified by silica gel column chromatography eluting first with PE:EtOAc (1:1) and then EtOAc to give the product (1.44 g, 86.5% yield). MS (m/z): 499.2 (M+H).
Preparation 76 5-(4-Amino-2-fluorophenoxy)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazol-6-amine
The title compound is prepared essentially by the method of Preparation 41. MS (m/z): 343.1 (M+H).
Preparation 77 5-(Benzyloxy)-6-(6-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
To a solution of 5-(benzyloxy)-6-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (4 g, 10.3 mmol) in 1,4-dioxane (25 mL) is added bis(pinacolato)diboron (3 g, 11.8 mmol), dppf (0.3 g, 541 μmol), PdCl2(dppf) (0.42 g, 514 μmol) and KOAc (2 g, 20.4 mmol) under N2. After the reaction mixture is stirred at reflux for 5 hours, 5-bromo-2-methylpyridine (2.1 g, 12.2 mmol), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) (0.6 g, 519 μmol) and Cs2CO3 (4 g, 12.3 mmol) are added and the mixture is stirred at reflux overnight. The reaction mixture is cooled and filtered, the filtrate is concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (2:1) to give the product (1.9 g, 46.0% yield). MS (m/z): 400.1 (M+H).
Preparation 78 6-(6-Methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-ol
To a solution of 5-(benzyloxy)-6-(6-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (1.44 g, 3.60 mmol) in EtOH (50 mL) and EtOAc (50 mL) is added Pd/C (500 mg, 10% wt) under N2. The resulting mixture is degassed by evacuation and backfilled with nitrogen. Then the reaction mixture is stirred at RT under H2 atmosphere overnight. The reaction mixture is filtered. The filtrate is concentrated to give the product (982 mg, 88.0% yield). MS (m/z): 310.1 (M+H).
Preparation 79 5-(2-Fluoro-4-nitrophenoxy)-6-(6-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
The title compound is essentially made by the same method of Preparation 75. MS (m/z): 449.2 (M+H).
Preparation 80 3-Fluoro-4-(6-(6-methylpyridin-3-yl)-1H-indazol-5-yloxy)aniline
The title compound is prepared essentially by the method of Preparation 41. MS (m/z): 335.1 (M+H).
Preparation 81 1-(4-Bromo-2-fluorophenoxy)-2-fluoro-5-methyl-4-nitrobenzene
The title compound is prepared essentially by the same method of Preparation 75. 1H NMR (d6-dimethylsulfoxide (DMSO)) δ 8.20 (d, 1H), 7.80 (d, 1H), 7.42 (d, 1H), 7.30(d, 1H), 7.10(d, 1H).
Preparation 82 4-(4-Bromo-2-fluorophenoxy)-5-fluoro-2-methylaniline
The title compound is prepared essentially by the method of Preparation 53. MS (m/z): 315.8 (M+H).
Preparation 83 5-(4-Bromo-2-fluorophenoxy)-6-fluoro-1H-indazole
To a suspension of 4-(4-bromo-2-fluorophenoxy)-5-fluoro-2-methylaniline (5.2 g, 16.6 mmol) in water (100 mL) is added fluoroboric acid (6.06 g, 33.1 mmol) at RT. The solution is cooled to 0° C. and NaNO2 (1.71 g, 24.8 mmol) in water (2 mL) is added. The reaction is stirred at 0° C. for 40 min. CHCl3 (200 mL) is added. The organic phase is separated, dried over Na2SO4, and filtered. To the filtrate is added KOAc (7.31 g, 74.5 mmol) and 18-crown-6-ether (0.218 g, 0.82 mmol). The reaction is stirred at RT for 1 hour. The reaction mixture is washed with saturated aqueous sodium chloride, dried over Na2SO4, filtered and evaporated. The residue is washed with DCM and filtered to offer the desired product as a light yellow solid. The filtrate is purified by chromatography eluting with DCM then EtOAc:hexane (1:1) to give additional desired product. Both portions of the solid are combined to offer the desired product (3.2 g, 59% yield). MS (m/z): 324.8 (M+H).
Preparation 84 5-(4-Bromo-2-fluorophenoxy)-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
The title compound is prepared essentially by the method of Preparation 9. MS (m/z): 410.8 (M+H).
Preparation 85 N-(Diphenylmethylene)-3-fluoro-4-(6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yloxy)aniline
The mixture of 5-(4-bromo-2-fluorophenoxy)-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.97 g, 2.37 mmol), benzophenone imine (0.64 g, 3.56 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.10 g, 0.075 mol), Cs2CO3 (1.16 g, 3.56 mmol), Pd2(dba)3 (0.11 g, 0.12 mmol) in 1,4-dioxane (20 mL) is purged with nitrogen, heated to 100° C. and stirred overnight. The reaction mixture is cooled to RT, extracted with EtOAc, washed with saturated aqueous sodium chloride, dried over Na2SO4, filtered and concentrated (1.45 g). MS (m/z): 510 (M+H).
Preparation 86 3-Fluoro-4-(6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yloxy) aniline
To a solution of N-(diphenylmethylene-3-fluoro-4-(6fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yloxy)aniline (1.45 g, 2.85 mmol) in THF (30 mL) and water (5 mL) is added 1N aqueous HCl (5.69 mL, 5.69 mmol). The reaction is stirred at RT for 2 hours. EtOAc is added and the mixture is washed with saturated aqueous NaHCO3 solution, saturated aqueous sodium chloride, dried over Na2SO4, filtered and evaporated. The residue is purified by chromatography eluting with DCM then EtOAc:hexane (1:1) to offer the desired product as a pale gel (0.53 g, 54% yield). MS (m/z): 346 (M+H).
Preparation 87 Ethyl 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate
The title compound is essentially made by the same method of Preparation 75. MS (m/z): 430.1 (M+H).
Preparation 88 Ethyl 5-(2-fluoro-4-nitrophenoxy)-1H-indazole-6-carboxylate
To a solution of ethyl 5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (15 g, 35 mmol) in DCM (300 mL) is added trifluoroacetic acid (TFA) (30 mL), and stirred at RT overnight. DCM is evaporated. The residue is partitioned between EtOAc (800 mL) and 5% aqueous NaHCO3 (400 mL). The organic layer is washed with saturated aqueous sodium chloride, dried over MgSO4, and concentrated. The residue is purified by silica gel column chromatography eluting with PE:acetone (5:1) to afford the product (10.4 g, 86% yield). MS (m/z): 346.1 (M+H).
Preparation 89 Ethyl 5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole-6-carboxylate
The title compound is prepared essentially by the method of Preparation 11: MS (m/z): 360.1 (M+H).
Preparation 90 5-(2-Fluoro-4-nitrophenoxy)-1-methyl-1H-indazole-6-carboxylic acid
To a solution of ethyl 5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole-6-carboxylate (1.19 g, 3.5 mmol) in THF/H2O (15 mL/5 mL) is added LiOH (0.2 g, 8.3 mmol). After the reaction is stirred at RT for 2 hours, the solvents are removed. The residue is acidified with 2N HCl to pH 5, and extracted with EtOAc (50 mL). The organic phase is washed with saturated aqueous sodium chloride, dried and concentrated to give the product (1.1 g, 100% yield). MS (m/z): 332.0 (M+H).
Preparation 91 tert-Butyl 5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-ylcarbamate
The suspension of 5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole-6-carboxylic acid (1.1 g, 3.3 mmol), diphenyl phosphoryl azide (0.91 g, 3.3 mmol), TEA (0.33 g, 3.3 mmol) and 4 Å molecular sieve (2.5 g) in tert-butanol (50 mL) is heated at reflux overnight. Then the solid is filtered off and the filtrate is concentrated. The residue is partitioned between saturated aqueous sodium chloride (40 mL) and EtOAc (100 mL). The organic phase is separated, dried and concentrated and the residue is purified by silica gel column chromatography eluting with PE:acetone (4:1) to give the product (0.64 g, 47.9% yield). MS (m/z): 403.1 (M+H).
Preparation 92 tert-Butyl 5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-ylcarbamate
The title compound is prepared essentially by the method of Proparation 38. MS (m/z): 373.1 (M+H).
Preparation 93 5-(5-(Benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-amine
to a solution of 5-(benzyloxy)-6-bromo-1-(tetrahydri-2H-pyran-2yl)-1H-indazole (1.5 g, 3.87 mmol) in 1,4-dioxane (50 mL) is added 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1 g, 4.54 mmol), Pd(PPh3)4 (200 mg, 173 μmol) and Cs2CO3 (5 g, 10.6 mmol). After the reaction mixture is stirred at reflux overnight, it is partitioned between EtOAc (100 mL) and saturated aqueous NH4Cl (50 mL). The organic phase is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (15:1) to give the product (0.80 g, 51.5% yield). MS (m/z): 401.1 (M+H).
Preparation 94 tert-Butyl 5-(5-(benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-ylcarbamate
To a solution of 5-(5-(benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-amine (310 mg, 774 μmol) in THF (20 mL) is added di-tert-butyldicarbonate (250 mg, 1.13 mmol) and TEA (1 mL, 7.17 mmol). After the reaction mixture is stirred at RT for 3 hours, it is partitioned between EtOAc (50 mL) and saturated aqueous NH4Cl (20 mL). The organic phase is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the product (260 mg, 67.1% yield). MS (m/z): 501.2 (M+H).
Preparation 95 tert-Butyl 5-(5-hydroxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-ylcarbamate
To a solution of tert-butyl 5-(5-(benzyloxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-ylcarbamate (260 mg, 519 μmol) in EtOH (25 mL) and EtOAc (25 mL) is added Pd/C (100 mg, 10% wt) under N2. The resulting mixture is degassed by evacuation and backfilled with nitrogen. Then the reaction mixture is stirred at RT under H2 atmosphere for 6 hours. The reaction mixture is filtered. The filtrate is concentrated to give the product (200 mg, 93.8% yield). MS (m/z): 411.1 (M+H).
Preparation 96 tert-Butyl 5-(5-(2-fluoro-4-nitrophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-ylcarbamate
The title compound is essentially made by the same method of Preparation 75. MS (m/z): 550.2 (M+H).
Preparation 97 tert-Butyl 5-(5-(4-amino-2-fluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)pyridin-2-ylcarbamate
The title compound is prepared essentially by the method of Preparation 38. MS (m/z): 520.2 (M+H).
Preparation 98 tert-Butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
5-(2-Fluoro-4-nitrophenoxy)-1-methyl-6-(1 H-pyrazol-4-yl)-1H-indazole (1.56 g, 4.42 mmol) in DCM (15.6 mL) is added di-tert-butyldicarbonate (1.09 mL, 4.83 mmol). The mixture is stirred for 30 min. HPLC shows the reaction is complete. The solvent is removed under reduced pressure. Then MTBE (5 mL) is added. The solution is cooled with ice water bath and stirred for 15 min, then filtered to give the title compound as a solid (0.764 g, 48.9%).
Preparation 99 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole
To a 3000 mL flask is added 6-bromo-5-(2-fluoro-4-nitrophenoxy)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (250 g, 573.1 mmol) followed by MeOH (1000 mL) and MeSO3H (1 12.71 mL,1.72 mol) and heated to 50° C. for 14 hours. Solid crystallizes out of solution. The mixture is then cooled to RT. The reaction mixture is concentrated under vacuum at 45° C. to dryness to get solid. The solid is diluted with DCM (2000 mL) and treated with water (1000 mL) and 5N NaOH (about 350 mL) until the pH is 8-9. The organic layer is separated and the solvent is removed followed by azeotrope with toluene to give 195.6 g of the yellow solid material. MS (m/z): 354.0 (M+H).
Preparation 100 6-Bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-i H-indazole
To a 4000 mL flask is added 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1H-indazole (230 g, 653.2 mmol), DMF (3000 mL), and K2CO3 (135.41 g, 979.78 mmol). The reaction mixture is cooled to 4.5° C. with an ice bath. To the mixture is added methyl iodide (92.71 g, 653.19 mmol) and the reaction is allowed to stir for 20 min at the same temperature. The reaction is allowed to warm to RT and stir for 13 hours. The reaction mixture is monitored by liquid chromatography mass spectrometry. Additional methyl iodide (50 g) and NaHCO3 (33 g) are added and the reaction mixture is stirred at RT until the reaction is completed. The reaction mixture is divided into two portions labeled (A) and (B), and each one is quenched with water (1 L) followed by extraction with EtOAc (1 L) causing some solids to form. The combined solids from (A) and (B) are collected by vacuum filtration to give 70 g of crude weight having about 90% 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole (which is the desired isomer) and 8% 6-bromo-5-(2-fluoro-4-nitrophenoxy)-2-methyl-2H-indazole isomers. This solid is then triturated with 1000 mL of DCM and 750 mL of MeOH overnight (about 14 hours). The solid is collected by filtration and rinsed with fresh DCM (100 mL) to give 55.5 g of desired material labeled (C). The mother liquor is concentrated and labeled (D). The organic layer from (A) and (B) are separated and concentrated. The residues from (A) and (B) are combined to give 185 g of crude as an orange solid labeled (E).
The crude compound (E) is dissolved in MeOH and DCM, and then the solution is divided into 3 portions. 600 g of silica gel is mixed with each portion of solution, and then the silica gel mixture is loaded into seven 270 g size empty cartridges. Seven 1.5 kg ISCO® columns are used with solvent system starting with 25% EtOAc in hexanes, then it is switched to 50% EtOAc in hexanes to give 62 g of the desired compound as a yellow powder labeled (F). After 7 runs, there are some mixed fractions of 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole and 6-bromo-5-(2-fluoro-4-nitrophenoxy)-2-methyl-2H-indazole isomers. The fractions are combined and combined with mother liquor (D) from the procedure described above to give 17 g of the mixture. The mixture is dissolved in MeOH and DCM, mixed with 170 g of silica into the solution, and run on a 1.5 kg column to give 10 g of a yellow powder as the desired product labeled (G). Total yield (55.5 g (C), 62 g (F), and 10 g (G)) is 127.5 g.
Preparation 101 tert-Butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
To a 12 L round bottom flask equipped with overhead agitation, a thermocouple, heating mantle, condenser, and subsurface nitrogen sparge is added 1,4-dioxane (7.44 L) and water (1.67 L). The solution is purged with N2 (inlet tube). Next 6-bromo-5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazole (595 g, 1.63 mol) is added and the solution is purged with N2 again. tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (717.02 g, 2.44 mol), potassium phosphate tribasic N-hydrate (689.8 g, 3.25 mol), and 1,1′-Bis(di-tert-butylphosphino)ferrocene (7.71 g, 16.25 mmol) are added. Finally, Pd2(dba)3 (7.44 g, 8.13 mmol) is added. The solution is purged for 15 min and then heated at 60° C. for 12 hours. The reaction is not complete and more Pd2(dba)3 (7.44 g, 8.13 mmol) is added. The solution is again heated at 60° C. for 3 additional hours and the reaction is complete. 1,4-Dioxane is then removed (Buchi® bath temp 60° C.) and the residue is re-dissolved in 10 volumes (6 L) of DCM. Water (3 L) is added and then the layers are separated. The organic solution is dried over Na2SO4, filtered and concentrated to a dark oil (835 g). The material is not purified and is forward processed to the next step. The material is about 60% desired product and about 40% 5-(2-fluoro-4-nitrophenoxy)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indazole. The crude obtained is reprotected in the next step. It is assumed that 50% of the crude product is the 5-(2-fluoro-4-nitrophenoxy)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indazole.
To a 22 L round bottom flask with overhead agitation, thermocouple, 1 L addition funnel, N2 purge, and cooling bath is added a solution of crude 5-(2-fluoro-4-nitro-phenoxy)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indazole (835 g, 1. 18 mol) in DCM (6 L) of. di-tert-butyldicarbonate (283.69 g, 1.30 mol) dissolved in DCM (350 mL) of is added to an addition funnel. The solution is added dropwise over 48 min. After the reaction is complete, DCM is removed by rotary evaporation to give a dark oil. To the dark oil is added MTBE (2.5 L) and the oily solution is cooled to about 0-5° C. The solution is seeded with material obtained in Preparation 98. After seeding, crystallization is observed and the resulting slurry is stirred for 30-40 min. The pale yellow slurry is filtered over a polypropylene pad and the cake is washed with cold (0-5° C.) MTBE (1.5 L). The solids are dried in a 40° C. vacuum oven overnight to give the desired product (443 g, 60% crude yield). MS (m/z): 354.0 (M+H). The material is shown to be about 93-95% pure by HPLC and is therefore forward processed.
Preparation 102 tert-Butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
To a 3 gallon tank is added tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (433.0 g, 952.8 mmol) followed by THF (6.5 L) and Pd/C (21.65 g, 10% Pd/C and 21.65 g, 5% Pd/C). The mixture is heated to 35° C. under hydrogen gas for 2 hours. The reaction is then cooled to RT and allowed to stir under hydrogen gas overnight, then is heated to 40° C. under hydrogen gas for seven hours. An additional 2 g Pd/C (1 g, 10% Pd/C and 1 g, 5% Pd/C) is added and stirred under hydrogen gas for another hour and cooled to RT. The mixture is again stirred under hydrogen gas overnight and the reaction is completed. The mixture is filtered over a combination of GFF® and Watman® paper. The filtrate is concentrated to a slightly yellow solid (446 g, 110% recovery).
Preparation 103 Methyl 2-oxo-1,2-dihydropyridine-3-carboxylate
To a flask is added 2-hydroxynicotinic acid (10 g, 72 mmol), concentrated H2SO4 (2 mL) and MeOH (400 mL), followed by toluene (80 mL). The reaction mixture is heated to reflux overnight with a Dean-Stark trap. After cooling to RT, the mixture is filtered and the filtrate is concentrated. The residue is dissolved in DCM (200 mL), neutralized with saturated aqueous NaHCO3 to pH 7 and extracted with DCM (200 mL) for three times. The combined organic phases are dried and concentrated to give the desired product (8.2 g, 74% yield). MS (m/z): 153.9 (M+H).
Preparation 104 Methyl 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate
To a mixture of methyl 2-oxo-1,2-dihydropyridine-3-carboxylate (6.0 g, 39 mmol), 4-fluorophenylboronic acid (16.3 g, 116 mmol), cupric acetate (14 g, 78 mmol) and pyridine (12 g, 0.156 mol) in DCM (300 mL) is added 4 Å molecular sieves (5 g). The reaction mixture is stirred at RT overnight open to air. After the solids are filtered and washed with water, the filtrate is extracted with DCM (100 mL). The organic layer is dried over MgSO4 and concentrated. The residue is purified by silica gel column chromatography eluting with PE:DCM (2:1 to 0:1) to give the product (9.6 g, 100% yield). MS (m/z): 248.0 (M+H).
Preparation 105 Ethyl 2-(4-fluorophenyl)hydrazinecarboxylate
To a solution of 4-fluorophenylhydrazine hydrochloride (2 g, 12.05 mmol) in THF (60 mL) is added DIPEA (6 mL, 34.40 mmol), ethyl chloroformate (1.2 mL, 12.55 mmol) and 4-dimethylaminopyridine (0.16 g, 1.31 mmol). The mixture is stirred at RT for 4 hours. The reaction is diluted with water and extracted with EtOAc, the organic phase is washed with saturated aqueous sodium chloride, dried over Na2SO4 and concentrated. The residue is purified by column chromatography on silica gel, eluting with DCM then DCM:MeOH (80:1) to afford the title compound (1.92 g, 80.5% yield). MS (m/z): 199 (M+H).
Preparation 106 1-(4-Fluorophenyl)-2-methylhydrazine
To a mixture of LiAlH4 (1.1 g) in THF (15 mL) is added a solution of ethyl 2-(4-fluorophenyl)hydrazinecarboxylate (1.9 g, 9.59 mmol) in THF (10 mL) dropwise under nitrogen in an ice-salt bath. After the addition, the ice bath is removed and the mixture is heated to 60° C. overnight. The reaction is cooled and quenched with water. The precipitate is filtered and washed with EtOAc. The organic phase is separated, dried over Na2SO4, and concentrated. The residue is purified by flash chromatography, eluting with PE:EtOAc (80:1 to 60:1) to afford the title compound (1 g, 74% yield). MS (m/z): 141 (M+H).
Preparation 107 Ethyl 2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate
A mixture of 1-(4-fluorophenyl)-2-methylhydrazine (0.6 g, 4.28 mmol), diethyl 2-acetylmalonate (0.96 g, 4.75 mmol), and acetic acid (0.51 g, 8.49 mmol) in water (15 mL) is heated at 115° C. for 3 hours. The reaction is cooled and extracted with EtOAc twice. The organic phase is washed with saturated aqueous sodium chloride, dried over Na2SO4 and concentrated. The residue is purified by column chromatography on silica gel, eluting with DCM:MeOH (from 150:1 to 60:1) to afford the title compound (0.59 g, 49.5% yield). MS (m/z): 279 (M+H).
Preparation 108 (E)-2-(2-(4-Fluorophenyl)hydrazono)acetaldehyde
A solution of 4-fluorophenylhydrazine hydrochloride (1 g, 6 mmol) in THF (20 mL) is treated with DIPEA (3 mL, 18 mmol). Then oxalaldehyde (40% in water, 0.89 g, 6.0 mmol) in THF (10 mL) is added dropwise in an ice-bath. After the addition, the mixture is stirred at RT for 30 min, quenched with water, and extracted with EtOAc. The organic phase is washed with saturated aqueous sodium chloride, dried over Na2SO4 and concentrated to afford the crude title compound (0.97 g, 97% yield). MS (m/z): 167 (M+H).
Preparation 109 Ethyl 2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylate
Crude (E)-2-(2-(4-fluorophenyl)hydrazono)acetaldehyde (0.97 g, 5.8 mmol) is dissolved in EtOH (50 mL), and diethyl malonate (0.93 g, 5.8 mmol) and piperidine (0.2 mL, 2.0 mmol) are added. The mixture is heated at reflux overnight. The reaction mixture is then cooled and concentrated. The residue is diluted with water and extracted with EtOAc twice. The combined organic extracts are dried over Na2SO4 and concentrated. The residue is purified by column chromatography on silica gel, eluting with PE:EtOAc (from 3:1 to 1:1), to afford title compound (0.26 g, 17% yield of two steps) MS (m/z): 263 (M+H).
Preparation 110 Methyl 3-(4-fluorophenylamino)-3-oxopropanoate
To a solution of 4-fluoroaniline (4.4 mL, 45 mmol) in acetone is added TEA (8.5 mL, 67 mmol) and methyl malonyl chloride (7.2 mL, 67 mmol). The mixture is stirred at RT for 5 hours and then concentrated. After water (20 mL) is added, the residue is acidified with concentrated HCl to pH 3. The precipitate is collected by filtration and washed with PE to give the product (14.1 g, 100% yield). MS (m/z): 212.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 110:
Physical data
Prep. MS (m/z)
No. Chemical name (M + H)
111 Ethyl 3-oxo-3-(phenylamino)propanoate 208
112 Ethyl 3-(4-fluorophenylamino)-3-oxopropanoate 226.1
Preparation 113 Ethyl 1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate
To a solution of methyl 3-(4-fluorophenylamino)-3-oxopropanoate(10.1 g, 48 mmol) in EtOH (100 mL) is added trans-4-methoxy-3-buten-2-one (5.7 g, 57 mmol) and CH3ONa (3.1 g, 57 mmol). The mixture is heated at reflux overnight and then concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAC (from 5:1 to 2:1) to give the product (2.1 g, 16% yield). MS (m/z): 276.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 113:
Physical data
Prep. MS (m/z)
No. Chemical name (M + H)
114 Ethyl 1-(4-fluorophenyl)-5-methyl-2-oxo-1,2- 276.1
dihydropyridine-3-carboxylate
115 Ethyl 5-methyl-2-oxo-1-phenyl-1,2- 258.1
dihydropyridine-3-carboxylate
Preparation 116 (Z)-4-Aminopent-3-en-2-one
To a solution of 2,4-pentanedione (20.0 g, 0.2 mol) in water (20 mL) is added 25% aqueous ammonia (13.2 mL, 0.2 mol) dropwise at RT. The mixture is stirred at RT for 2 hours. Then the solvent is removed to give the product (20.0 g, 100% yield) as a solid. 1H NMR (Acetone-d6, 300 MHz): 1.88 (s, 3H), 1.88 (s, 3H), 2.8 (br s, 1H), 6.54 (br s, 1H), 9.7 (brs, 1H).
Preparation 117 Ethyl 4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylate
A solution of (Z)-4-aminopent-3-en-2-one (20.0 g, 0.2 mol) in dry THF (20 mL) is added to a solution of ethyl cyanoacetate (22.6 g, 0.2 mol) and TEA (20.2 g, 0.2 mol) in dry THF (200 mL). The reaction mixture is heated at reflux for 56 hours and then concentrated. The residue is kept standing at RT for 5 hours and the precipitate is filtered and washed with EtOAc to afford the title compound (7.3 g, 19.9% yield). MS (m/z): 196.0 (M+H).
Preparation 118 Ethyl 1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylate
A suspension of ethyl 4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylate (5.0 g, 0.025 mol), 4-fluorophenylboronic acid (10.7 g, 0.077 mol), cupric acetate (1.33 g, 0.007 mol), pyridine (6.86 mL), and 4 A molecular sieves (5.0 g) in 1,4-dioxane (80 mL) is heated at 80° C. for 68 hours. The solids are filtered off and the filtrate is concentrated. The residue is partitioned with EtOAc (50 mL) and 2N HCl (70 mL). The precipitated solid is collected by filtration and washed with EtOAc to give the title product (1.2 g). The EtOAc filtrate is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc:MeOH (40:20:1) to give another portion of product (0.12 g), (1.32 g total, 17.8% yield). MS (m/z): 290.1 (M+H).
Preparation 119 Ethyl 4,6-dimethyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate
A suspension of ethyl 4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylate (7.5 g, 0.038 mol), phenylboronic acid (14.1 g, 0.115 mol), cupric acetate (1.38 g, 0.008 mol), pyridine (7.5 mL) in 1,4-dioxane (80 mL) is heated at 80° C. for 96 hours. The solid is filtered off and the filtrate is concentrated. The residue is partitioned with EtOAc (50 mL) and 2N HCl (70 mL), and the precipitate is collected by filtration and washed with EtOAc to give the title product (2.95 g). The EtOAc solution is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with PE:acetone (2:1) to give another portion of (0.3 g). (3.25 g, 31.2% yield). MS (m/z): 272.0 (M+H).
Preparation 120 Ethyl 5-(bromomethyl)-2-(4-fluorophenyl)-1-methyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate
To a solution of ethyl 2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate (1.2 g, 4.3 mmol) and azobisisobutyronitrile (AIBN) (0.09 g, 0.06 mmol) in DCM is added N-bromosuccinimide (NBS) (0.9 g, 4.3 mmol) in three portions at RT. The resulting reaction mixture is stirred at RT overnight. The mixture is concentrated and the residue is purified by silica gel column chromatography eluting with PE:EtOAc (4:1) to give the product as a white solid (1.3 g, 84% yield). MS (m/z) 357.0 (M+H).
Preparation 121 Ethyl 5-((1H-pyrazol-1-yl)methyl)-2-(4-fluorophenyl)-1-methyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate
To a solution of ethyl 5-(bromomethyl)-2-(4-fluorophenyl)-1-methyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate (1.3 g, 3.6 mmol) and 1H-pyrazole (0.25 g, 3.6 mmol) in THF (50 mL) and H2O (1 mL) cooled in an ice-water bath is added solid KOH (0.2 g, 3.6 mmol) in three portions. After the reaction mixture is stirred at RT overnight, the solvent is removed. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (4:1) to give the product (0.87 g, 70% yield). MS (m/z): 345.1 (M+H).
The following compounds are prepared essentially by the method of Preparation 121:
Physical
data
MS (m/z)
Prep. No. Chemical name (M + H)
122 Ethyl 2-(4-fluorophenyl)-1-methyl-5- 364.1
(morpholinomethyl)-3-oxo-2,3-dihydro-1H-
pyrazole-4-carboxylate
123 Ethyl 2-(4-fluorophenyl)-1-methyl-3-oxo-5- 362.1
(piperidin-1-ylmethyl)-2,3-dihydro-1H-pyrazole-
4-carboxylate
Preparation 124 Ethyl 1-(4-fluorophenyl)-5-(morpholinomethyl)-2-oxo-1,2-dihydropyridine-3-carboxylate
A mixture of ethyl 1-(4-fluorophenyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (0.275 g, 1 mmol), NBS (0.2 g, 1.1 mmol), AIBN (40 mg, 0.2 mmol) in CCl4 (20 mL) is heated at reflux for 3 hours. After the reaction is cooled down, morpholine (0.088 mL, 1 mmol) and K2CO3 (0.14 g, 1 mmol) are added. The reaction is stirred at RT for another 2 hours. The solvent is removed, and the residue is diluted with water (10 mL) and extracted with EtOAc (20 mL) twice. The combined organic phases are washed with saturated aqueous sodium chloride, dried, and concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (from 100:1 to 50:1, containing 0.5% 2 N NH3 in MeOH), to afford the title compound (0.17 g, 47% yield). MS (m/z): 361.1 (M+H).
Preparation 125 Ethyl 2-(4-fluorophenylcarbamoyl)-3-methylbut-2-enoate
To a solution of 4-fluoroaniline (2 g, 18 mmol) in diethyl isopropylidenemalonate (10 g, 50 mmol) is added 1H-imidazole (0.25 g, 3.67 mmol). The reaction mixture is stirred at 200° C. under N2 for 3 hours. After the reaction is cooled, silica gel is added. The mixture is loaded onto a silica gel column, and eluted first with PE and then PE:EtOAc (3:1) to give the product (1.85 g, 39% yield). MS (m/z): 266.1 (M+H).
Preparation 126 Ethyl 1-(4-fluorophenyl)-4-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate
A mixture of ethyl 2-(4-fluorophenylcarbamoyl)-3-methylbut-2-enoate (1.85 g, 6.97 mmol) and N,N-dimethylformamide dimethyl acetal (5 mL, 37.45 mmol) is stirred at 90° C. for 90 min. After the reaction is cooled, EtOAc (30 mL) and saturated NH4Cl solution (20 mL) are added. The organic phase is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (10:1). The fractions containing product are concentrated, and the residue is mixed with ether to give 1.2 g of yellow solid which is filtered and discarded. The filtrate is concentrated and purified again by silica gel column chromatography eluting with DCM:MeOH (20:1) to give the product (500 mg, 26% yield). MS (m/z): 276.1 (M+H).
Preparation 127 Ethyl 2-(4-fluorophenyl)-6-methyl-3-oxo-2,3-dihydropyridazine-4-carboxylate
To a suspension of 1-triphenylphosphoranylidene-2-propanone (3.18 g, 9.99 mmol) in THF (50 mL) is added diethyl ketomalonate (1.74 g, 9.99 mmol). The resulting mixture is stirred at RT for 30 min to give a clear solution. Then this solution is added to a solution of 4-fluorophenylhydrazine hydrochloride (1.62 g, 9.96 mmol) in EtOH:H2O (30 mL:30 mL). After the resulting mixture is refluxed for 1 hour, TEA (3 mL) is added and the mixture is stirred at reflux for another 1 hour. Then it is concentrated and the residue is partitioned with saturated aqueous NH4Cl (30 mL) and EtOAc (30 mL). The organic phase is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with PE:EtOAc (3:1) to give the product (1.20 g, 43% yield). MS (m/z): 277.1 (M+H).
Preparation 128 1-(4-Fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
To a solution of methyl 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate (10.0 g, 0.04 mol) in MeOH (150 mL) and water (50 mL) is added LiOH (1.9 g, 0.08 mol). The resulting reaction mixture is stirred at RT for 0.5 hour. After most of the MeOH is removed, the mixture is acidified with concentrated aqueous HCl until a white solid precipitates. The solid is collected by filtration and washed with water (5 mL) to give the desired product (8.7 g, 93% yield). MS (m/z): 234.0 (M+H).
The following compounds are prepared essentially by the method of Preparation 128:
Physical
data
Prep. MS (m/z)
No. Chemical name (M + H)
129 2-(4-Fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro- 251
1H-pyrazole-4-carboxylic acid
130 2-(4-Fluomphenyl)-3-oxo-2,3-dihydropyridazine-4- 235
carboxylic acid
131 1-(4-Fluorophenyl)-6-methyl-2-oxo-1,2-dihydro- 248.1
pyridine-3-carboxylic acid
132 1-(4-Fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydro-
pyridine-3-carboxylic acid
133 4,6-Dimethyl-2-oxo-1-phenyl-1,2-dihydro-pyridine- 244.0
3-carboxylic acid
 134* 5-((1H-Pyrazol-1-yl)methy1)-2-(4-fluorophenyl)-1-
methyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic
acid
 135** 2-(4-Fluorophenyl)-1-methyl-5-(morpholinomethyl)- 336.1
3-oxo-2,3- dihydro-1H-pyrazole-4-carboxylic acid
136 2-(4-Fluorophenyl)-1-methyl-3-oxo-5-(piperidin-1- 334.1
ylmethyl)-2,3-dihydro-1H-pyrazole-4-carboxylic
acid
137 1-(4-Fluorophenyl)-5-methyl-2-oxo-1,2-dihydro- 248.0
pyridine-3-carboxylic acid
138 5-Methyl-2-oxo-l-phenyl-1,2-dihydropyridine-3- 230.1
carboxylic acid
139 1-(4-Fluorophenyl)-5-(morpholinomethyl)-2-oxo-1,2- 333.1
dihydropyridine-3-carboxylic acid
 l40** 1-(4-Fluorophenyl)-4-methyl-2-oxo-1,2- 248.1
dihydropyridine-3-carboxylic acid
141 2-(4-Fluorophenyl)-6-methyl-3-oxo-2,3- 249.0
dihydropyridazine-4-carboxylic acid
*KOH is used as the base.
**NaOH is used as the base.
Preparation 142 6-Methyl-2-oxo-1-phenyl-1,2-dihydro-pyridine-3-carboxylic acid
To a solution of sodium ethoxide in EtOH (prepared from sodium (0.5 g, 21.75 mmol) dissolved in EtOH (40 mL)) is added ethyl 3-oxo-3-(phenylamino)propanoate (4 g, 19.30 mmol) and trans-4-methoxy-3-buten-2-one (2 g, 19.98 mmol). After the reaction is stirred at reflux overnight, the mixture is concentrated. The residue is partitioned between H2O (50 mL) and EtOAc (50 mL). The aqueous layer is acidified with concentrated HCl to a pH 3˜4 and then it is extracted with EtOAc. The organic extracts are dried and concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (25:1) to give the product (1.20 g, 27% yield). MS (m/z): 230.0 (M+H).
Preparation 143 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid
To a mixture of 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbaldehyde (2 g, 9.25 mmol) in water (100 mL) at 75° C. is added a solution of KMnO4 (1.5 g, 9.49 mmol) in water (200 mL) slowly. After the addition is complete, the reaction mixture is stirred at 75° C. for another 1 hour. Solid KOH is added to make the solution alkaline and the mixture is filtered while it is hot. To the filtrate is added EtOH (10 mL) and EtOAc (50 mL). The organic phase is separated and discarded. The aqueous phase is acidified with concentrated HCl to pH 5 and extracted with EtOAc (60 mL) and DCM (60 mL). The organic phases are combined, dried, and concentrated to give the title product (1.9 g, 88.46%yield). MS (m/z): 233.1 (M+H).
Preparation 144 Ethyl 3-(4-fluorophenylamino)-3-oxopropanoate
To a 4-necked 10 L round bottom flask, is added DCM (5000 mL), 4-fluoroaniline (111 g, 1.0 mol) and TEA (166 mL, 1.2 mol). Ethyl malonyl chloride (196 g, 1.3 mol) in DCM (500 mL) is added dropwise under N2 at 0-5° C. (under ice bath) during 4 hours. After addition, the mixture is stirred for 30 min at this temperature. Water (2 L) is added into the mixture with stirring at this temperature. The organic phase is washed with saturated NaHCO3, saturated aqueous sodium chloride and dried over anhydrous Na2SO4. The aqueous phase is extracted with EtOAc (2×1 L). The organic phase is washed with saturated aqueous sodium chloride and dried over anhydrous Na2SO4. After filtration, the residue is washed with PE (1 L) to give ethyl 3-(4-fluorophenylamino)-3-oxopropanoate (230 g, crude yield 102%) as a yellow solid. MS (m/z): 226.1 (M+H).
Preparation 145 1-(4-Fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
To a 4-necked 3 L round bottom flask, is added EtOH (1500 mL), ethyl 3-(4-fluorophenylamino)-3-oxopropanoate (139 g, 617 mmol), sodium ethoxide (65.6 g, 925 mmol) and 4-methoxy-3-buten-2-one (103 g, 925 mmol). The mixture is refluxed for 3 hours. After the solution is cooled to RT, the reaction mixture is concentrated under reduced pressure to remove the EtOH. The residue is diluted with DCM (700 mL) and 1 M HCl (1500 mL). The aqueous phase is extracted with DCM (3×500 mL). The combined organic extracts are washed with saturated aqueous sodium chloride (1000 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue is triturated with EtOAc (150 mL) at RT (10-15° C.) for 1 hour. After filtration and washing with EtOAc (50 mL), 1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid is obtained as a yellow solid (85.3 g, 56% yield). MS (m/z): 248 (M+H).
Example 1 N-(3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
Figure USRE043878-20121225-C00007
To a 100 mL round bottom flask is added tert-butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (1.43 g, 3.38 mmol), 1-(4-flurorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (1.25 g, 5.07 mmol), EDCI (1.48 g, 7.6 mmol) and HOBt (776 mg, 5.07 mmol) followed by DMF (15 mL, 193.99 mmol) and then DIPEA (1.47 mL, 8.44 mmol). The mixture is allowed to stir at RT overnight. The reaction mixture is diluted into EtOAc (300 mL) and washed with saturated aqueous sodium chloride (5×100 mL). The combined aqueous solution is extracted with EtOAc (1×100 mL) and then the combined organic solutions are dried over N2SO4, filtered, and concentrated to dryness. The solid is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in a DCM solution (B), gradient from 100% (A) to 80% (A):20% (B) over 70 min to give tert-butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate as a gold solid (2.20 g, 87% yield). MS (m/z): 653. (M+H), 675 (M+Na).
To a round bottom flask is added tert-butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (1.92 g, 2.94 mmol) and DCM (50 mL) followed by triethylsilane (1.88 mL, 11.77 mmol) and TFA (17.8 mL, 235.35 mmol). The reaction mixture is allowed to stir at RT for 1.5 hours. The solvent is removed and diluted into DCM (150 mL) and washed with saturated aqueous NaHCO3 solution (2×100 mL). The organic solution is dried with Na2SO4, and concentrated under reduced pressure to give a solid material. The solid is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in DCM solution (B), gradient from 100% (A) to 75%(A):25%(B) over 70 min, held at this 75:25 ratio for 15 min to give the title compound as an off-white solid. The solid is dissolved in hot EtOH (50 mL) followed by a portion-wise addition of distilled water (250 mL) causing a white solid to precipitate. The solid is filtered over a Buchner funnel and washed with distilled water (3×15 mL), air dried, and vacuum dried at 60° C. for 15 hours to give the title compound as an off-white solid (1.27 g, 78% yield). MS (m/z): 552.8 (M+H).
Example 2 N-(3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
Figure USRE043878-20121225-C00008
A 12 L round bottom flask is equipped with overhead agitation, a thermocouple, and a N2 purge. tert-Butyl 4-(5-(4-amino-2-fluorophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (404 g, 954.08 mmol) is dissolved in DMF (2 L) and charged to the flask. DMF (1 L) is used to rinse the flask. 1-(4-Fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (259.46 g, 1.05 mol) and EDCI (228.63 g, 1.19 mol) are added and it is rinse in with DMF (500 mL). Then HOBt (189.94 g, 1.24 mol) is added and it is again rinsed in with DMF (500 mL). Finally, DIPEA is slowly added (184.97 g, 1.43 mol). The dark solution is then stirred at RT over the weekend. To a 20 L bottom outlet flask is added DI water (3 L) and DCM (5 L). The reaction mixture is poured in and it is rinsed in with DCM (1 L). The organic layer is separated, washed with DI water (3×3 L), dried over Na2SO4, filtered, rinsed solids with DCM and concentrated the filtrate. EtOAc (2 L) is added to the residue and the solution is stirred for 1 hour. The product crystallizes out. The mixture is concentrated. Another portion of EtOAc (2 L) is added and concentrated to remove all of the DCM. EtOAc (650 mL) and MTBE (3 L) are added to the residue and the solution is stirred in an ice bath for 1 hour. The tan slurry is filtered using a polypropylene pad. The cake is rinsed with MTBE (2×500 mL). The light tan solid is dried overnight in the vacuum oven at 40° C. to give the crude product (553 g). The crude product is purified by silica gel column chromatography eluting with (50% EtOAc (50%):35% DCM (35%): n-heptane (15%)) to give the pure desired product tert-butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (424 g, 68%). MS (m/z): 651.0 (M−H).
tert-Butyl 4-(5-(2-fluoro-4-(1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate (423.9 g, 649.50 mmol) is dissolved in DCM (4.24 L). HCl in MeOH (5.74 N, 799.99 mL, 4.59 mol) is added and the solution is heated at 30° C. for 1 hour. Then the reaction mixture is heated to 45° C. and DCM (1.5 L) is added. After two hours, the solution is heated to 50° C. and DCM (2 L) is added. After 3 hours, DCM (2 L) is added followed by HCl in MeOH (4.5 N, 721.67 mL, 3.25 mol). After another 45 min, DCM (1 L), HCl in MeOH (4.5 N, 288.67 mL, 1.30 mol), and MeOH (1.5 L) are added. The reaction solution is then heated to 60° C. After 4 hours, MeOH (2 L) is added and 10 min later DCM (1 L) is added followed by HCl in MeOH (4.5 N, 200 mL). After 5 hours, the reaction is complete. The reaction mixture is concentrated to about ⅓ volume. MeOH (2 L) is added and the solution is concentrated to a thick slurry. Again, MeOH (2 L) is added and the mixture is concentrated to a thick slurry. The slurry is cooled to about 10-15° C. and then filtered. The solids are washed with MeOH. The solids are placed in a 55° C. vacuum oven for 2 days to give the desired product N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide hydrochloride (377 g, 92.8%). MS (m/z): 551.0 (M−H).
To a 22 L round bottom flask equipped with mechanical stirring under nitrogen is added N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide hydrochloride (367 g, 0.62 mol) followed by DCM (7.34 L) and water (7.34 L). Na2CO3 (181.6 g, 1.71 mol) is added and the mixture is stirred at RT for 30 min. The pH is checked and found to be about 9.4. The mixture is filtered over polypropylene. The solids are collected and placed into a 5 L round bottom flask. A 20% water/MeOH solution (2.6 L) is added and the slurry is stirred for 30 min. The slurry is filtered and the solids are washed with 20% water/MeOH (600 mL). The solids are placed in a vacuum oven at 35° C. overnight. The first weighing indicates 394 g (theoretical yield 324.8 g, about 121% mass recovery). TGA (Thermogravimetric analysis)/DSC (differential scanning calorimetry) shows about 17 wt % free water and 10-11 wt% volatile loss at the melt. The solids are dried at 55° C. in a vacuum oven with a N2 sweep for 3.5 hours (354.7 g, about 109% mass recovery, NMR shows about 9.3 wt % DCM). No free water is present according to TGA/DSC. The material is sent for milling.
The jet mill (Aljet™ 0101) in a glove bag is assembled inside a walk in hood and hooked up to N2 to a 100 lb header. The inlet pusher nozzle is adjusted for maximum draw and max nitrogen flow is introduced into the mill. Pressure readings are noted as 90 psi on pusher nozzle and 85 psi on both grind nozzles. The starting material (353.4 g) is slowly fed to the mill inlet, stopping to empty the receiver sock as needed. The total milling time is 22 min and 25 second. The calculated feed rate is 15.8 g/min (353.4 grams divided by 22.42 min). The milled material (335.7 g, 95%) is obtained with 17.7 g loss. Particle size analysis result of the milled material is d90 of 4.6 microns.
TGA/DSC indicates about 11.4 wt % volatiles at the melt and NMR (DMSO) shows about 9.3 wt % DCM. 1H NMR (DMSO) δ 12.94 (br s, 1 H), 11.88 (s, 1H), 8.44 (d,J=7.47 Hz, 1 H), 8.12 (br s, 1 H), 8.00 (br s, 1 H), 7.96 (s, 1 H), 7.94 (d,J=2.2 Hz, 1 H), 7.91 (d,J=2.6 Hz, 1 H), 7.87 (s, 1H), 7.47-7.37 (m, 5 H), 6.82 (t,J=9.26 Hz, 8.82 Hz, 1 H), 6.65 (d,J=7.49 Hz, 1 H), 4.04 (s, 3 H), 2.03 (s, 3 H). LC/MS: (M+H) 553.1.
Anhydrous Crystal Form Preparation
To 10 mL of EtOH is added 120 mg of the above compound into a 20 mL vial. The sample is heated to 70° C. with stirring. Initially the solids start to dissolve and then a suspension forms followed by a white precipitate. The sample is cooled to RT while being stirred. A small sample of the slurry is taken by pipette and allowed to air dry. This material is highly crystalline and proves to be an ethanol solvate by TGA. To the remaining suspension, 10 mL of heptane is added and then heated to boiling. The measured temperature is monitored at 70.8° C. until the volume has been reduced to 10 mL. When the temperature starts to rise, the heat is removed and the slurry stirred at RT overnight. The solid is isolated by vacuum filtration and dried in a vacuum oven at 45° C. for 3 hours, resulting in 77% recovery. The crystalline form shows a weight loss of 0.17% from 25-238° C. by TGA. The form's onset of melting is 247.8° C.
Example 3 N-(3-Fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide methanesulfonate
Figure USRE043878-20121225-C00009
To a solution of 3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)aniline (300 mg, 927.8 μmol) and 1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (300 mg, 1. 15 mmol) in DMF (5 mL) is added HOBt (130 mg, 0.962 mmol), EDCI (180 mg, 0.939 mmol) and N-methylmorpholine (0.5 mL). After the reaction mixture is stirred at 60° C. overnight, it is partitioned between EtOAc (50 mL) and saturated aqueous NH4Cl (30 mL). The organic phase is separated, dried and concentrated. The residue is triturated with EtOAc (5 mL) and the solids are collected by filtration to give N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide as the desired product (230 mg, 43.7% yield.) MS (m/z): 567.2 (M+H).
To a solution of N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide (230 mg, 0.406 mmol) in acetone (10 mL) is added MeSO3H (39 mg, 0.406 mmol). After the reaction is stirred at RT for 0.5 hour, it is concentrated. The residue is washed with ether and dried to give N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide methanesulfonate (250 mg, 92.9% yield.) MS (m/z): 567.2 (M+H).
The following compounds are prepared essentially by the method of Example 3 with the exception that in certain cases the freebase is generated and not the salt:
Physical
data
Ex. MS (m/z)
No. Chemical name Structure (M + H)
4 1-(4-Fluorophenyl)-6- methyl-N-(4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2- pxp-1,2-dihydropyridine- 3-carboxamide methanesulfonate
Figure USRE043878-20121225-C00010
 		535.2
5 N-(3-Fluoro-4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-6- methyl-2-oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00011
 		535.1
6 N-(3-Fluoro-4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-4,6- dimethyl-2-oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00012
 		549.1
7 N-(3-Fluoro-4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2-(4- fluorophenyl)-1,5-dimethyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00013
 		556.2
8 N-(3-Fluoro-4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide methanesulfonate
Figure USRE043878-20121225-C00014
 		540.2
9 N-(3-Fluoro-4-(1-methyl-6- (2-methylpyridin-4-yl)-1H- indazol-5-yloxy)phenyl)-1-(4- fluorophenyl)-6-methyl-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00015
 		578.1
10 6-Methyl-N-(4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2- oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00016
 		517.2
11 5-((1H-Pyrazol-1-yl)methyl)- N-(3-fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 2-(4-fluorophenyl)-1-methyl- 3-oxo-2,3-dihydro-1H- pyrazole-4-carboxamide
Figure USRE043878-20121225-C00017
 		627.2
12 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-6-methyl- 2-oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00018
 		558.1
13 N-(4-(6-(Dimethylamino)- indazol-5-yloxy)-3- fluorophenyl)-6-methyl-2- oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00019
 		498.2
14 N-(3-Fluoro-4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-1-(4- fluorophenyl)-5-methyl-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00020
 		553.1
15 N-(3-Fluoro-4-(6-(pyridin-3- yl)-1H-indazol-5- yloxy)phenyl)-1-(4- fluorophenyl)-6-methyl-2- oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00021
 		550.2
16 5-((1H-Pyrazol-1-yl)methyl)- N-(4-(6-(dimethylamino)-1H- indazol-5-yloxy)-3- fluorophenyl)-2-(4- fluorophenyl)-1-methyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00022
 		585.1
17 l-(4-Fluorophenyl)-4,6- dimethyl-N-(4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00023
 		549.2
18 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00024
 		544.2
19 N-(3-Fluoro-4-(6-(tetrahydro- 2H-pyran-4-ylamino)-1H- indazol-5-yloxy)phenyl)-1-(4- fluorophenyl)-4,6-dimethyl-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00025
 		586.1
20 N-(4-(6-(Dimethylamino)-1H- indazol-5-yloxy)-3- fluorophenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide
Figure USRE043878-20121225-C00026
 		503.1
21 N-(4-(6-(Dimethylamino)-1H- indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-4,6-dimethyl-2- oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00027
 		530.2
22 N-(4-(6-(Dimethylamino)-1H- indazol-5-yloxy)phenyl)-6- methyl-2-oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00028
 		480.2
23 N-(3-Fluoro-4-(6-(6- methylpyridin-3-yl)-1H- indazol-5-yloxy)phenyl)-1-(4- fluorophenyl)-6-methyl-2- oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00029
 		564.1
24 4,6-Dimethyl-N-(4-(1-methyl- 6-(1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2- oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00030
 		531.2
25 N-(3-Fluoro-4-(1-methyl-6- (pyridin-3-yl)-1H-indazol-5- yloxy)phenyl)-2-(4- fluorophenyl)-1,5-dimethyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00031
 		567.1
26 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00032
 		544.1
27 5-Methyl-N-(4-(1-methyl-6- (1H-pyrazol-4-yl)-1H- indazol-5-yloxy)phenyl)-2- oxo-1-phenyl-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00033
 		517.1
28 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 2-(4-fluorophenyl)-1-methyl- 5-(morpholinomethyl)-3-oxo- 2,3-dihydro-1H-pyrazole-4- carboxamide methanesulfonate
Figure USRE043878-20121225-C00034
 		646.2
29 N-(3-Fluoro-4-(6-(pyridin-3- yl)-1H-indazol-5- yloxy)phenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00035
 		535.5
30 N-(3-Fluoro-4-(6-(pyridin-3- yl)-1H-indazol-5- yloxy)phenyl)-2-(4- fluorophenyl)-1-methyl-5- (morpholinomethyl)-3-oxo- 2,3-dihydro-1H-pyrazole-4- carboxamide
Figure USRE043878-20121225-C00036
 		638.2
31 N-(3-Fluoro-4-(6-(pyridin-4- yl)-1H-indazol-5- yloxy)phenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide methanesulfonate
Figure USRE043878-20121225-C00037
 		537.1
32 N-(3-Fluoro-4-(6-(pyridin-4- yl)-1H-indazol-5- yloxy)phenyl)-2-(4- fluorophenyl)-1,5-dimethyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00038
 		553.2
33 N-(3-Fluoro-4-(6-(pyridin-3- yl)-1H-indazol-5- yloxy)phenyl)-2-(4- fluorophenyl)-1,5-dimethyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00039
 		553.1
34 N-(4-(6-(1H-Pyrazol-4-yl)- 1H-indazol-5-yloxy)-3- fluorophenyl)-2-(4- fluorophenyl)-6-methyl-3- oxo-2,3-dihydropyridazine-4- carboxamide methanesulfonate
Figure USRE043878-20121225-C00040
 		540.1
35 N-(4-(6-Dimethylamino)-1H- indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-6-methyl-2- oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00041
 		516.2
36 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy(phenyl)- 1-(4-fluorophenyl)-5- (morpholinomethyl)-2-oxo- 1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00042
 		643.2
37 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-4-methyl- 2-oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00043
 		558.1
38 N-(3-Fluoro-4-(6-(6- methylpyridin-3-yl)-1H- indazol-5-yloxy(phenyl)-1-(4- fluorophenyl)-4,6-dimethyl-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00044
 		578.1
39 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 2-(4-fluorophenyl)-6-methyl- 3-oxo-2,3-dihydropyridazine- 4-carboxamide
Figure USRE043878-20121225-C00045
 		559.2
40 N-(4-(6-(1,3-Dimethyl-1H- pyrazol-5-yl)-1H-indazol-5- yloxy)-3-fluorophenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide
Figure USRE043878-20121225-C00046
 		554.2
41 N-(3-Fluoro-4-(6-(pyridin-4- yl)-1H-inadazol-5- yloxy(phenyl)-1,5-dimethyl- 3-oxo-2-phenyl-2,3-dihydro- 1H-pyrazole-4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00047
 		535.2
42 N-(3-Fluoro-4-(6-morpholino- 1H-indazol-5-yloxy)phenyl)- 2-(4-fluorophenyl)-2-oxo-2,3- dihydropyridazine-4- carboxamide
Figure USRE043878-20121225-C00048
 		545.1
43 N-(4-(6-(1,3-Dimethyl-1H- pyrazol-5-yl)-1H-indazol-5- yloxy)-3-fluorophenyl)-1-(4- fluorophenyl)-4,6-dimethyl-2- oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00049
 		581.1
44 N-(4-(6-(2,6- Dimethylpyridin-4-yl)-1H- indazol-5-yloxy)-3- fluorophenyl)-2-(4- fluorophenyl)-1,5-dimethyl-3- oxo-2,3-dihydro-1H-pyrazole- 4-carboxamide methanesulfonate
Figure USRE043878-20121225-C00050
 		581.2
45 N-(3-Fluoro-4-(6-(2- methylpyridin-4-yl)-1H- indazol-5-yloxy)phenyl)-2-(4- fluorophenyl)-1-methyl-3- oxo-5-(piperidin-1-ylmethyl)- 2,3-dihydro-1H-pyrazole-4- carboxamide
Figure USRE043878-20121225-C00051
 		650.1
46 N-(3-Fluoro-4-(6-(2- methoxypyrimidin-5-yl)-1H- indazol-5-yloxy)phenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00052
 		567.2
47 N-(3-Fluoro-4-(6-(2- methylpyridin-4-yl)-1H- indazol-5-yloxy)phenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide
Figure USRE043878-20121225-C00053
 		551.2
Example 48 N-(4-(6-Amino-1-methyl-1H-indazol-5-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-6-methyl1-2-oxo-1,2-dihydropyridine-3-carboxamide methanesulfonate
Figure USRE043878-20121225-C00054
To a 10 mL screw-cap vial is added 5-(4-amino-2-fluorophenoxy)-N-benzhydryl-1-methyl-1H-indazol-6-amine (91 mg, 208 μmol), 1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (66.7 mg, 269.78 μmol), EDCI (90.9 mg, 466.9 μmol) and HOBt (47.7 mg, 311.3 μmol) followed by DMF (2 mL, 25.9 mmol). To the mixture is added DIPEA (90.5 μL, 518.8 μmol) and the mixture is stirred at RT for 12 hours. Additional EDCI (50 mg), HOBt (25 mg), DIPEA (0.02 mL), and 1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (40 mg) are added and the mixture is stirred for an additional 24 hours. The reaction is diluted into EtOAc (100 mL) and washed with saturated aqueous sodium chloride (3×25 mL). The combined aqueous solution is extracted with EtOAc (1×25 mL). The combined organic solution is dried over Na2SO4, filtered, and concentrated to dryness. The residue is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in DCM solution (B), gradient from 100% (A) to 90%(A): 10%(B) over 60 min to give a clear wax material as the desired product (114 mg, 82% yield). MS (m/z) 667.8 (M+H).
To a 25 mL round bottom flask is added N-(4-(6-(benzhydrylamino)-1-methyl-1H-indazol-5-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 149.7 μmol) and DCM (15 mL, 15.6 mmol) followed by the addition of triethylsilane (0.3 mL, 1.8 mmol) and TFA (2 mL, 26.9 mmol). The reaction mixture is stirred at RT for 3 hours. The solvent is removed and then the residue is diluted in DCM (50 mL) and washed with a saturated NaHCO3 solution (1×25 mL). The aqueous layer is extracted with DCM (1×25 mL) and the combined organic solution is dried with Na2SO4, filtered and concentrated. The residue is purified on a silicas gel column eluting wiht DCM (A) and a 10% MeOH in a DCM solution (B), gradient from 100% (A) to 80%(A):20%(B) over 50 min, held at 80:20 ratio for 5 min then gradient to 70%(A):30%(B) over 5 min to give a white solid material as the desired product (67 mg, 90% yield). MS (m/z): 501.8 (M+H).
to a round bottom flask is added N-(4-(6-amino-1-methyl-1H-indazol-5-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (47.5 mg, 94.7 μmol) in DCM (2 mL, 31.2 mmol) and MeOH (2 mL, 49.4 mmol). MeSO3H (6.2 μL, 94.7 μmol) in MeOH is added. The solution is concentrated to give a light yellow solid (54 mg, 96% yield). MS (m/z): 501.8 (M+H).
The following compounds are prepared essentially by the method of Example 48:
Physical
data
Ex. MS (m/z)
No. Chemical name Structure (M + H)
49 N-(4-(6-Amino-1-methyl-1H- indazol-5-yloxy)-3- fluorophenyl)- 1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00055
 		487.8
Example 50 N-(4-(6-Amino-1H-indazol-5-yloxy)-3-fluorophenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide methanesulfonate
Figure USRE043878-20121225-C00056
To a solution of tert-butyl 5-(4-amino-2-fluorophenoxy)-1H-indazol-6-ylcarbamate (170 mg, 474 μmol) and 6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid (120 mg, 0.52 mmol) in DMF (5 mL) is added HOBt (60 mg, 0.44 mmol), EDCI (90 mg, 0.47 mmol) and N-methylmorpholine (0.5 mL). After the reaction mixture is stirred at 60° C. overnight, it is partitioned between EtOAc (50 mL) and saturated aqueous NH4Cl (30 mL). The organic phase is separated, dried and concentrated, and the residue is purified by silica gel column chromatography eluting with PE:EtOAc (1:1) to give the product (65 mg, 24. 1% yield) MS (m/z): 570.2 [M+H]).
To a solution of tert-butyl 5-(2-fluoro-4-(6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamido)phenoxy)-1H-indazol-6-ylcarbamate (65 mg, 0.114 mmol) in DCM (10 mL) is added TFA (1 mL, 13.5 mmol). After the reaction is stirred at RT overnight, it is concentrated. The residue is partitioned with saturated aqueous NaHCO3 (30 mL) and DCM (50 mL), and the organic phase is separated, dried and concentrated. The residue is purified by silica gel column chromatography eluting with DCM:MeOH (20:1) to give the product (35 mg, 65.3% yield). MS (m/z): 470.1 (M+H).
To a solution of N-(4-(6-amino-1H-indazol-5-yloxy)-3-fluorophenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (35 mg, 74.6 μmol) in acetone (10 mL) is added MeSO3H (7.16 mg, 74.6 μmol). After the reaction mixture is stirred at RT for 0.5 hour, it is concentrated. The residue is washed with ether and dried to give N-(4-(6-amino-1H-indazol-5-yloxy)-3-fluorophenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide methanesulfonate (39 mg, 92.5% yield). MS (m/z): 470.1 (M+H).
The following compounds are prepared essentially by the method of Example 50:
Physical
data
Ex. MS (m/z)
No. Chemical name Structure (M + H)
51 N-(4-(6-Amino-1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4-fluorophenyl)-2- oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00057
 		474.1
52 N-(4-(6-Amino-1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4-fluorophenyl)-4,6- dimethyl-2-oxo-1,2-dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00058
 		502.2
53 N-(4-(6-Amino-1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4-fluorophenyl)-6- methyl-2-oxo-1,2-dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00059
 		488.1
54 N-(4-(6-(6-Aminopyridin-3-yl)-1H- indazol-5-yloxy)-3-fluorophenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4-carboxamide
Figure USRE043878-20121225-C00060
 		552.1
Example 55 N-(3-Fluoro-4-(6-(2-methylmorpholino)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
Figure USRE043878-20121225-C00061
To a 10 mL screw-cap vial is added 3-fluoro-4-(6-(2-methylmorpholino)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-yloxy)aniline (44 mg, 103.17 μmol), 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (42 mg, 0.18 mmol), EDCI (45.177 mg, 232.13 μmol), HOBT (23.699 mg, 154.75 μmol) followed by DMF (5 mL, 64.66 mmol) and DIPEA (44.980 μL, 257.92 μmol). The reaction mixture is stirred at RT overnight. The reaction is diluted into EtOAc (50 mL) and washed with saturated aqueous sodium chloride (5×25 mL). Organic layers are dried over Na2SO4, filtered, and concentrated to dryness. The residue is purified on a silica gel column eluting with hexanes (A) and EtOAc (B), gradient from 80% (A): 20% (B) to 30% (A): 70% (B) over 40 min, hold at 30:70 ratio for 15 min to give a yellow solid as desired product N-(3-fluoro-4-(6-(2-methylmorpholino)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (70 mg, 99% yield). MS (m/z): 641.8 (M+H).
To a round bottom flask is added N-(3-fluoro-4-(6-(2-methylmorpholino)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (66 mg, 102.86 μmol) and MeOH (5 mL, 123.54 mmol). To the resulting mixture is added MeSO3H (20.229 μL, 308.57 μmol) and the reaction mixture is heated to 40° C. for 6 hours. The reaction mixture is concentrated and dissolved in DCM (100 mL). The solution is washed with a mixture of saturated aqueous sodium chloride (20 mL) and saturated aqueous sodium bicarbonate solution (1×20 mL). The organic solution is extracted with DCM (1×25 mL) and dried over Na2SO4, filtered and concentrated. The residue is purified on a silica gel column eluting with DCM (A) and a 10% MeOH in DCM solution (B), gradient from 100% (A) to 70%(A):30%(B) over 60 min to give a light yellow solid as the desired product (40 mg, 62% yield). MS (m/z): 557.8 (M+H).
The following compounds are prepared essentially by the method of Example 55:
Physical
data
Ex. MS (m/z)
No. Chemical name Structure (M + H)
56 (R)-N-(3-Fluoro-4-(6-(2- methylmorpholino)-1H- indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-2- oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00062
 		558.2
57 (R)-N-(3-Fluoro-4-(6-(2- methylmorpholino)-1H- indazol-5-yloxy)phenyl)- 1-(4-fluorophenyl)-6- methyl-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00063
 		572.2
58 N-(4-(6-Cyclopropyl- 1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00064
 		499
59 N-(4-(6-Cyclopropyl- 1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-6-methyl- 2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00065
 		512.8
60 N-(4-(6-((2S,6R)-2,6- Dimethylmorpholino)- 1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00066
 		572.2
61 N-(4-(6-(2,2- Dimethylmorpholino)- 1H-indazol-5-yloxy)-3- fluorophenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00067
 		572.2
62 N-(3-Fluoro-4-(6- morpholino-1H-indazol- 5-yloxy(phenyl)-1-(4- fluorophenyl)-4,6- dimethyl-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00068
 		571.8
63 N-(3-Fluoro-4-(6-(4- (methylsulfonyl)phenyl)- 1H-indazol-5- yloxy)phenyl)-1-(4- fluorophenyl)-2-oxo-1,2- dihydropyridine-3- carboxamide
Figure USRE043878-20121225-C00069
 		613.1
 64* N-(3-Fluoro-4-(6-fluoro- 1H-indazol-5- yloxy(phenyl)-1-(4- fluorophenyl)-6-methyl- 2-oxo-1,2- dihydropyridine-3- carboxamide methanesulfonate
Figure USRE043878-20121225-C00070
 		491.2
65 5-(2-Fluoro-4-(1-(4- fluorophenyl)-6-methyl- 2-oxo-1,2- dihydropyridine-3- carboxamido)phenoxy)- N-(tetrahydro-2H-pyran- 4-yl)-1H-indazole-6- carboxamide
Figure USRE043878-20121225-C00071
 		600.2
*Methanesulfonate salt is prepared essentially by the same method of salt formation step in Example 3.
The following assays demonstrate that certain compounds of the present invention potently inhibit c-Met phosphorylation in cells, potently inhibit c-Met in vivo, and demonstrate dose dependent anti-tumor activity in certain xenograft models.
c-Met Protein Expression and Purification
The kinase domain (KD) of human c-Met (from Gly 966 to Ser 1390, NCBI NM—000245) is cloned into a pFastBac® RHT vector (Invitrogen, Carlsbad, Calif.). The His-c-Met KD construct is transposed into Baculovirus DNA using a Bac-to-Bac® system (Invitrogen). SF9 cells are infected with the recombinant baculovirus. The infected cells are harvested by centrifugation and the cell pellet is collected and stored at −80° C. Cells are lysed in buffer A (40 mM tris(hydroxymethyl)aminomethane (Tris), pH 7.5, 500 mM NaCl, 20% glycerol, and 10 mM imidazole). Cell lysates are homogenized and centrifuged. Supernatants are incubated with nickel-nitrilotriacetic (Ni—NTA) resin and loaded onto a column. Proteins are eluted with buffer B (buffer A plus 0.3 M imidazole) and c-Met containing fractions are pooled together, loaded onto a Superdex®200 column (Amershan Bioscience, Piscataway, N.J.), eluted with buffer C (40 mM Tris, pH 7.5, 250 mM NaCl, and 10% glycerol).
HGF Stimulated Met (pY1349) NCI-H460 Cell-based ELISA
NCI-H460 cells (purchased from ATCC) are cultured in RPMI 1640 media (Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS) and plated (prior to becoming 70% confluent) in 96-well flat-bottom plates at a density of 20,000 cells per well in 80 μL volume. The cells are then incubated overnight in a cell culture incubator (5% CO2, 95% Relative Humidity (RH) and 37° C.) and allowed to attach to the plate. The following morning the cells are washed with 2 volumes of a Reduced Serum Media (RSM) (RPMI 1640 media supplemented with 0.5% FBS). After removal of the last wash, 80 μL of RSM is added to each well of the cell plates. The cell plates are incubated for 2.5 hours in a cell culture incubator, and then dosed with compounds. Compound inhibitors are first solubilized at 10 mM in 100% DMSO and then diluted to 100 μM with 2% DMSO RSM. Subsequently compound serial dilutions (1:3) are prepared over a 100 μM to 0.005 μM range. Cells are dosed with the addition of 20 μL of compound stock to produce a final DMSO concentration of 0.4% and a final compound concentration dose range between 20 and 0.001 μM. After dosing with compounds the cells plates are gently agitated to mix and then allowed to incubate for 30 min in a cell culture incubator. After dose completion, the cells are stimulated with the addition of 20 μL per well of Hepatocyte Growth Factor (HGF) at a final concentration of 100 ng/mL in RSM (all wells except MIN wells are stimulated, MIN wells are dosed with 20 μL RSM). After 10 min incubation in a cell culture incubator, the liquid is removed from the cell plate wells, and the cells are lysed by the addition of 50 μL of ice-cold Meso Scale Discovery® (MSD, Gaithersburg, Md.) 1× Lysis Buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, and 1% TRITON® X-100) supplemented with Phosphatase I and II and Protease inhibitors (Sigma, St. Louis, Mo.). After lysis at RT for 30 min the lysates are transferred to and captured on a MSD® Multi-Spot 96-well 4-spot PhosphoMet plate that is BSA-blocked (at 30 mg/mL Block A in 1× Tris Wash Buffer) and then washed one time with Tris Wash Buffer. After 2 hours capture (at RT) the lysates are removed from the MSD® plate and the plate is washed with 1X Tris Wash Buffer. After blotting, 25 μL of 5 nM Sulfo-Tag Anti-Total Met antibody (detection antibody, MSD® prepared in 1× Tris Wash Buffer supplemented with 10 mg/mL BSA and 0.1% Blocker D-R (MSD®)) is added to the wells of the MSD® plate. After 1 hour capture (at RT) the MSD® plate wells are washed with 1× Tris Wash Buffer, and then 150 μL of 1× Read Buffer T (with surfactant, MSD®) is added. Immediately after the addition of the Read Buffer, the plates are analyzed with a SECTOR 6000 MSD® Imager plate reader. Relative IC50 values are determined using MSD activity units by calculating percent inhibition with respect to on-plate “MIN” and “MAX” controls and then fitting the percent inhibition values and ten-point dose response data to a four-parameter logistic equation. This assay has a Minimum Significant Ratio (MSR) of 2.06. For all exemplified compounds the IC50 values are less than 0.2 μM. For example, the average (n=6) IC50 value (50% inhibitory concentration ) of Example 1 in this assay is 0.0352 μM, indicating it potently inhibits c-Met phosphorylation in cells.
c-Met In Vivo Target Inhibition Assay
S114 cells (licensed from PHS, over-express both human HGF and human c-Met) are cultured in a growth media (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal calf serum and expanded. Cells are harvested and washed twice with phosphate buffered saline and 2×106 cells are mixed with equal volume of BD Matrigel™ matrix (BD Bioscience, Franklin, N.J.), and injected subcutaneously into the flank of nude mice (athymic nude, from Harlan, Indianapolis, Ind.). At day 8 after implant, compounds (formulated in 10% acacia or 1% carboxymethylcellulose/0.5% sodium lauryl sulfate/0.05% antifoam as suspension) are administered to animals by oral gavage at 50 mg/kg. Animals are sacrificed at 2 hours post dose, and tumors are harvested and stored frozen until needed.
Frozen tumors are pulverized using motar-pastel. The pulverized tissues are transferred to a tube containing Lysing Matrix D beads (MP Biomedicals, Solon, Ohio) and 600 μL lysis buffer (RIPA buffer, containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, from Boston Bioproducts). A FastPrep® Cell Disrupter (MP Biomedicals) is used to disrupt the tissue and lyse the cells. Lysates are passed through a 20 gauge needle and transferred to a clean tube. Protein concentration is determined by Bradford method.
Tumor lysates are loaded onto MSD® phosphor-Met ELISA plates and phosphor-c-Met level is determined using the same protocol as H460 cell-based ELISA. For all exemplified compounds the S114 in vivo inhibition values are equal or greater than 50% at the dose of 50 mg/kg. For example, Example 1 is a potent inhibitor of c-Met phosphorylation with an ED50 value (dose that produces 50% inhibition in tumor of 2.9 mg/kg, indicating it is a potent c-Met inhibitor in vivo.
Xenograft Tumor Models
Human glioblastoma cells U87MG, human gastric cancer cells MKN45, human non small cell lung cancer cells H441, and human renal carcinoma cells Caki-1 are expanded in culture, harvested, and injected subcutaneously onto the rear flank of athymic nude mice. Testing compound is prepared in an appropriate vehicle and is administered by oral gavage when tumors are established (7-21 days after implant). Tumor response is determined by tumor volume measurement performed twice a week during the course of treatment. Tumor volume inhibition (% growth inhibition) is calculated by comparing treated groups to a vehicle control group. Body weight is taken as a general measurement of toxicity. The Compound of Example 1 demonstrates excellent dose dependent anti-tumor activity in these models. For example, when dosed at 1.3 mg/kg (oral (PO), bi-daily (BID)×35), Example 1 is able to cause 59% growth inhibition of U87MG tumors. At 4 mg/kg dose (PO, BID×35), 82% growth inhibition is achieved. At 12 mg/kg dose (PO, BID×3 5), 92% growth inhibition reaches.
c-Met Relevant Tumors and Xenograft Models
c-Met overexpression is a common feature for many human tumors, including lung, breast, colorectal, gastric, renal, pancreatic, head and neck (1,2). c-Met activating mutations in the kinase domain are implicated as the cause for several tumors, such as hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer (3-7). c-Met inhibitors from Pfizer demonstrated antitumor efficacy in many human xenograft tumors, including U87MG, GTL16, H441, Caki-1, and PC3 (8).
    • 1. Christinsen, J G., Burrows, J., and Salgia, R. Cancer Letters 225:1-26, 2005.
    • 2. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, GF. Nat Rev Mol Cell Biol 4: 915-925, 2003.
    • 3. Di Renzo, M F., Olivero, M., Martone, T. Et al. Oncogene 19:1547-1555, 2000.
    • 4. Lee, J H., Han, SU, Cho, H. et al. Oncogene 19: 4947-4953, 2000.
    • 5. Ma, P C., Kijima, T., Maulik, G. et al. Cancer Res 63: 6272-6281, 2003.
    • 6. Park, W S., Dong, S M., Kim, S Y. et al. Cancer Res 59: 307-310, 1999.
    • 7. Schmidt, L., Duh, F M., Chen, F., et al. Nat Genet 16: 68-73, 1997.
    • 8. Zou, H Y., Li, Qiuhua., Lee, J H., et al. Cancer Res 67: 4408-4417, 2007.
The compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration. Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al., eds., 19th ed., Mack Publishing Co., 1995).
The compounds of Formula I are generally effective over a wide dosage range. For example, dosages per day normally fall within the range of about 1 mg to about 200 mg total daily dose, preferably 1 mg to 150 mg total daily dose, more preferably 1 mg to 50 mg total daily dose. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed. The above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Claims (15)

1. A compound of the formula:
Figure USRE043878-20121225-C00072
wherein:
R1 is H or methyl;
R2 is amino, dimethylamino, fluoro, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazolyl optionally substituted with two methyl substituents, 2-methoxy-pyrimidin-5-yl, 4-methylsulfonylphenyl, tetrahydro-2H-pyran-4-ylamino, (tetrahydro-2H-pyran-4-yl)amino carbonyl, or a morpholin-4-yl substituent:
Figure USRE043878-20121225-C00073
where Ra, Rb and Rc are independently selected from H or methyl;
R3 is H or F;
R4 is H, methyl, piperidin-1-ylmethyl, morpholin-4-ylmethyl, or pyrazol-1-ylmethyl;
R5 is H or F; and
X is CH═N, CH═CH, CH═C(CH3), C(CH3)═CH, C(CH3)═N, N(CH3), or C(morpholin-4ylmethyl)═CH C(morpholin-4-ylmethyl)═CH;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is amino, dimethylamino, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazol-4-yl, or a morpholin-4-yl.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is amino, dimethylamino, pyrazol-4-yl, or a morpholin-4-yl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is pyrazol-4-yl.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is H, methyl, or morpholin-4-ylmethyl.
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is H.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is CH═CH or CH═C(CH3).
8. The compound according to claim 1 which is N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 which is N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.
11. The compound according to claim 1 wherein the particle size is less than 10 microns.
12. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof the formula:
Figure USRE043878-20121225-C00074
wherein:
R1 is H or methyl;
R2 is amino, dimethylamino, fluoro, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazolyl optionally substituted with two methyl substituents, 2-methoxy-pyrimidin-5-yl, 4-methylsulfonylphenyl, tetrahydro-2H-pyran-4-ylamino, (tetrahydro-2H-pyran-4-yl)amino carbonyl, or a morpholin-4-yl substituent;
Figure USRE043878-20121225-C00075
where Ra, Rb and Rc are independently selected from H or methyl;
R3 is H or F;
R4 is H, methyl, piperidin-1-ylmethyl, morpholin-4-ylmethyl, or pyrazol-1-ylmethyl;
R5 is H or F; and
X is CH═N, CH═CH, CH═C(CH3), C(CH3)═CH, C(CH3)═N, N(CH3), or C(morpholin-4-ylmethyl)═CH;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
13. A method of treating cancer selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, hereditary papillary renal cell carcinoma, childhood hepatocellular carcinoma, and gastric cancer in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof the formula:
Figure USRE043878-20121225-C00076
wherein:
R1 is H or methyl;
R2 is amino, dimethylamino, fluoro, cyclopropyl, pyridyl optionally substituted with an amino substituent or 1-2 methyl substituents, pyrazolyl optionally substituted with two methyl substituents, 2-methoxy-pyrimidin-5-yl, 4-methylsulfonylphenyl, tetrahydro-2H-pyran-4-ylamino, (tetrahydro-2H-pyran-4-yl)amino carbonyl, or a morpholin-4-yl substituent;
Figure USRE043878-20121225-C00077
where Ra, Rb and Rc are independently selected from H or methyl;
R3 is H or F;
R4 is H, methyl, piperidin-1-ylmethyl, morpholin-4-ylmethyl, or pyrazol-1-ylmethyl;
R5 is H or F; and
X is CH═N, CH═CH, CH═C(CH3), C(CH3)═CH, C(CH3)═N, N(CH3), or C(morpholin-4-ylmethyl)═CH;
or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition according to claim 12 wherein the compound is N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.
15. The method according to claim 13 wherein the compound is N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.
US13/374,053 2008-07-24 2011-12-08 Amidophenoxyindazoles useful as inhibitors of c-Met Expired - Fee Related USRE43878E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/374,053 USRE43878E1 (en) 2008-07-24 2011-12-08 Amidophenoxyindazoles useful as inhibitors of c-Met

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27
US12/503,223 US8030302B2 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-Met
US13/374,053 USRE43878E1 (en) 2008-07-24 2011-12-08 Amidophenoxyindazoles useful as inhibitors of c-Met

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/503,223 Reissue US8030302B2 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-Met

Publications (1)

Publication Number Publication Date
USRE43878E1 true USRE43878E1 (en) 2012-12-25

Family

ID=41010247

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/503,223 Ceased US8030302B2 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-Met
US13/374,053 Expired - Fee Related USRE43878E1 (en) 2008-07-24 2011-12-08 Amidophenoxyindazoles useful as inhibitors of c-Met

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/503,223 Ceased US8030302B2 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-Met

Country Status (36)

Country Link
US (2) US8030302B2 (en)
EP (1) EP2310382B1 (en)
JP (1) JP5414794B2 (en)
KR (1) KR101334456B1 (en)
CN (1) CN102105462B (en)
AR (1) AR074632A1 (en)
AT (1) ATE546444T1 (en)
AU (1) AU2009274256B2 (en)
BR (1) BRPI0916286B8 (en)
CA (1) CA2731773C (en)
CL (1) CL2011000134A1 (en)
CO (1) CO6351737A2 (en)
CR (1) CR20110046A (en)
CY (1) CY1112595T1 (en)
DK (1) DK2310382T3 (en)
DO (1) DOP2011000009A (en)
EA (1) EA018385B1 (en)
EC (1) ECSP11010778A (en)
ES (1) ES2379587T3 (en)
HK (1) HK1155172A1 (en)
HR (1) HRP20120202T1 (en)
IL (1) IL210490A (en)
JO (1) JO2788B1 (en)
MA (1) MA32594B1 (en)
MX (1) MX2011000925A (en)
MY (1) MY163852A (en)
NZ (1) NZ590013A (en)
PE (1) PE20110150A1 (en)
PL (1) PL2310382T3 (en)
PT (1) PT2310382E (en)
RS (1) RS52261B (en)
SI (1) SI2310382T1 (en)
SV (1) SV2011003816A (en)
TW (1) TWI365185B (en)
WO (1) WO2010011538A1 (en)
ZA (1) ZA201100219B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5734193B2 (en) 2008-10-14 2015-06-17 クイ ニング Compounds and methods of use
AU2010229147B2 (en) 2009-03-21 2012-07-05 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
JP5970003B2 (en) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド Aminopyrazine compounds
KR20130118612A (en) * 2012-04-20 2013-10-30 (주)네오믹스 Novel aminopyridine derivatives and use thereof
EP2870178B1 (en) * 2012-05-09 2017-07-12 Eli Lilly and Company Anti-c-met antibodies
JP6433922B2 (en) * 2013-02-27 2018-12-05 アレイ バイオファーマ、インコーポレイテッド Intermediates for use in the preparation of indazole derivatives and methods for their preparation
CN104140393B (en) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 A kind of preparation method of aromatic ring/heteroaromatic tert-butyl alcohol ester type compound
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (en) * 2015-08-12 2017-05-16 應克隆公司 Combination therapy for cancer
EP3442573A1 (en) 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
CN109952319B (en) 2016-06-02 2023-08-25 英美偌科有限公司 Quantitative dosing regimen for gp100 specific TCR-anti-CD 3 scFv fusion proteins
WO2018022438A1 (en) * 2016-07-29 2018-02-01 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (en) * 2016-11-15 2018-05-25 中国药科大学 2,4- disubstituted pyridines and its preparation method and application
WO2018093669A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN109982700A (en) * 2016-11-16 2019-07-05 伊莱利利公司 The treatment of cancer with the jump of exons 14 mutation or the jump phenotype of exons 14
CN107382968A (en) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 A kind of preparation method of indoles c Met inhibitor
CN107311983A (en) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 Indoles micromolecular C MET inhibitor
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
EP3719012B1 (en) 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
JP7282397B2 (en) * 2018-01-17 2023-05-29 薬捷安康（南京）科技股▲分▼有限公司 TAM family kinase/and CSF1R kinase inhibitor and use thereof
KR102221689B1 (en) 2018-03-08 2021-03-02 웰마커바이오 주식회사 Thienopyridine derivatives and pharmaceutical composition comprising same
AU2019323455B9 (en) * 2018-08-24 2024-10-24 Transthera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
WO2020048455A1 (en) 2018-09-03 2020-03-12 泰励生物科技（上海）有限公司 Trk inhibitor as anti-cancer drug
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
US20240293386A1 (en) * 2021-06-22 2024-09-05 Lg Chem, Ltd. Novel compound as protein kinase inhibitor
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608049B2 (en) 2000-09-18 2003-08-19 Bayer Aktiengesellschaft Indazoles
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20060211695A1 (en) 2004-06-28 2006-09-21 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
WO2007075567A1 (en) 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008008539A2 (en) 2006-07-14 2008-01-17 Amgen Inc. Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
WO2008051808A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (en) * 1982-04-23 1987-03-11 Sintef PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DK1400808T3 (en) * 2001-05-18 2006-10-23 Srl Inc immunoassay
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (en) * 2002-04-24 2004-03-04 Japan Science & Technology Corp Cross-linked polymer, fine particle and method for production
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
EP1649284B1 (en) * 2003-07-17 2007-12-05 Invitrogen Dynal AS Process for preparing coated magnetic particles
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
EP2230264B1 (en) * 2006-06-29 2019-10-09 Life Technologies AS Particles containing multi-block polymers

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608049B2 (en) 2000-09-18 2003-08-19 Bayer Aktiengesellschaft Indazoles
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20060004006A1 (en) 2004-06-28 2006-01-05 Borzilleri Robert M Pyrrolotriazine kinase inhibitors
US20060211695A1 (en) 2004-06-28 2006-09-21 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
WO2007075567A1 (en) 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008008539A2 (en) 2006-07-14 2008-01-17 Amgen Inc. Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
WO2008051808A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
US9598400B2 (en) 2011-02-28 2017-03-21 Calitor Sciences, Llc Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
CO6351737A2 (en) 2011-12-20
RS52261B (en) 2012-10-31
NZ590013A (en) 2012-06-29
IL210490A0 (en) 2011-03-31
CN102105462B (en) 2014-07-23
MA32594B1 (en) 2011-09-01
SV2011003816A (en) 2011-03-17
AR074632A1 (en) 2011-02-02
TW201006817A (en) 2010-02-16
ES2379587T3 (en) 2012-04-27
CN102105462A (en) 2011-06-22
CA2731773A1 (en) 2010-01-28
CY1112595T1 (en) 2016-02-10
IL210490A (en) 2013-06-27
KR101334456B1 (en) 2013-11-29
MY163852A (en) 2017-10-31
BRPI0916286B8 (en) 2021-05-25
JO2788B1 (en) 2014-03-15
CR20110046A (en) 2011-04-27
PT2310382E (en) 2012-04-11
EA018385B1 (en) 2013-07-30
DK2310382T3 (en) 2012-03-26
ECSP11010778A (en) 2011-02-28
TWI365185B (en) 2012-06-01
EA201170252A1 (en) 2011-06-30
AU2009274256A1 (en) 2010-01-28
ZA201100219B (en) 2012-06-27
EP2310382B1 (en) 2012-02-22
HK1155172A1 (en) 2012-05-11
AU2009274256B2 (en) 2013-07-11
CA2731773C (en) 2013-03-12
US8030302B2 (en) 2011-10-04
DOP2011000009A (en) 2011-03-31
EP2310382A1 (en) 2011-04-20
JP5414794B2 (en) 2014-02-12
PL2310382T3 (en) 2012-07-31
KR20110022691A (en) 2011-03-07
JP2011529054A (en) 2011-12-01
HRP20120202T1 (en) 2012-03-31
WO2010011538A1 (en) 2010-01-28
PE20110150A1 (en) 2011-03-07
MX2011000925A (en) 2011-03-21
BRPI0916286B1 (en) 2019-10-08
ATE546444T1 (en) 2012-03-15
US20100022529A1 (en) 2010-01-28
CL2011000134A1 (en) 2011-07-08
SI2310382T1 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
USRE43878E1 (en) Amidophenoxyindazoles useful as inhibitors of c-Met
JP6377081B2 (en) New pyrimidine compounds
AU2023203524A1 (en) Substituted heterocyclyl derivatives as cdk inhibitors
DK2137162T3 (en) Organic compounds and their applications
AU2012299899B2 (en) Bicyclic heteroaromatic compounds
AU2020255100C1 (en) N-heteroaromatic amide derivatives for treatment of cancer
JP5518887B2 (en) Tetrasubstituted pyridazine hedgehog pathway antagonist
EP2242749A1 (en) Novel pyridinones and pyridazinones
CA2728408A1 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
TW201302730A (en) Pyrazole compounds
US9353107B2 (en) 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
US20150166505A1 (en) Pyridinyl-substituted pyrazolyl carboxamides
EA015574B1 (en) Triazolyl aminopyrimidine compounds
JP2023547346A (en) Potent and selective novel compounds as serotonin 1B receptor modulators
KR20210048701A (en) Novel pyridinyltriazine derivatives as protein kinase inhibitors and compositions for preventing, improving or treating cancer containing the same
KR101127725B1 (en) Amide derivative

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY